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Abstract
The rapidly progressing field of nanotechnology promises to revolutionize healthcare in the 21st century,
with applications in the prevention, diagnosis, and treatment of a wide range of diseases. However, before
nanoparticulate agents can be brought into clinical use, they must first be developed, optimized, and
evaluated in animal models. In the typical pre-clinical paradigm, almost all of the optimization is done at
the in vitro level, with only a few select agents reaching the level of animal studies. Since only one
experimental nanoparticle formulation can be investigated in a single animal, and in vivo experiments
have relatively higher complexity, cost, and time requirements, it is not feasible to evaluate a very large
number of agents at the in vivo stage. A major drawback of this approach, however, is that in vitro assays
do not always accurately predict how a nanoparticle will perform in animal studies. Therefore, a method
that allows many agents to be evaluated in a single animal subject would allow for much more efficient
and predictive optimization of nanoparticles. We have found that by incorporating lanthanide tracer
metals into nanoparticle formulations, we are successfully able to use inductively coupled plasma mass
spectrometry (ICP-MS) to quantitatively determine a nanoparticle's blood clearance kinetics,
biodistribution, and tumor delivery. This approach was applied to evaluate both passive and active tumor
targeting, as well as metabolically directed targeting of nanoparticles to low pH tumor
microenvironments. Importantly, we found that these in vivo measurements could be made for many
nanoparticle formulations simultaneously, in single animals, due to the high-order multiplexing capability
of mass spectrometry. This approach allowed for efficient and reproducible comparison of performance
between different nanoparticle formulations, by eliminating the effects of subject-to-subject variability. In
the future, we envision that this "higher-throughput" evaluation of agents at the in vivo level, using ICP-MS
multiplex analysis, will constitute a powerful tool to accelerate pre-clinical evaluation of nanoparticles in
animal models.
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ABSTRACT

ICP-MS ANALYSIS OF LANTHANIDE-DOPED NANOPARTICLES: A
QUANTITATIVE AND MULTIPLEXING APPROACH TO INVESTIGATE
BIODISTRIBUTION, BLOOD CLEARANCE, AND TARGETING

Samuel Crayton

Andrew Tsourkas, Ph.D.

The rapidly progressing field of nanotechnology promises to revolutionize healthcare in
the 21st century, with applications in the prevention, diagnosis, and treatment of a wide
range of diseases. However, before nanoparticulate agents can be brought into clinical
use, they must first be developed, optimized, and evaluated in animal models. In the
typical pre-clinical paradigm, almost all of the optimization is done at the in vitro level,
with only a few select agents reaching the level of animal studies. Since only one
experimental nanoparticle formulation can be investigated in a single animal, and in vivo
experiments have relatively higher complexity, cost, and time requirements, it is not
feasible to evaluate a very large number of agents at the in vivo stage. A major drawback
of this approach, however, is that in vitro assays do not always accurately predict how a
nanoparticle will perform in animal studies. Therefore, a method that allows many agents
to be evaluated in a single animal subject would allow for much more efficient and
predictive optimization of nanoparticles. We have found that by incorporating lanthanide
tracer metals into nanoparticle formulations, we are successfully able to use inductively
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coupled plasma mass spectrometry (ICP-MS) to quantitatively determine a nanoparticle’s
blood clearance kinetics, biodistribution, and tumor delivery. This approach was applied
to evaluate both passive and active tumor targeting, as well as metabolically directed
targeting of nanoparticles to low pH tumor microenvironments. Importantly, we found
that these in vivo measurements could be made for many nanoparticle formulations
simultaneously, in single animals, due to the high-order multiplexing capability of mass
spectrometry. This approach allowed for efficient and reproducible comparison of
performance between different nanoparticle formulations, by eliminating the effects of
subject-to-subject variability. In the future, we envision that this “higher-throughput”
evaluation of agents at the in vivo level, using ICP-MS multiplex analysis, will constitute
a powerful tool to accelerate pre-clinical evaluation of nanoparticles in animal models.
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Chapter 1: Introduction to Nanoparticle Diversity, Applications,
Delivery, and Detection
1.1 Introduction
Extensive research is currently underway on a global scale to develop
nanotechnology for applications in the prevention, diagnosis, and treatment of disease.
Such innovations have the potential to revolutionize healthcare in the 21st century by
improving quality of life, extending life expectancy, and reducing healthcare costs.1
Already, nanoparticles platforms are being applied to diverse fields including
regenerative medicine,2 vaccines,3 imaging,4, 5 surgery,6 and drug delivery.7, 8 Given the
variety of materials used in nanoparticle synthesis, the breadth of their applications, and
growth of active targeting molecules, the number of distinct nanoparticle formulations is
truly astronomical.
In order to evaluate the performance of any nanoparticle formulation, a central
consideration is what amount of nanoparticles (or nanoparticle payload) has reached the
particular site of interest. It is also important to examine the amount of nanoparticles
delivered to off-target tissues, since this can lead to increased toxicity in drug delivery
studies and diminished contrast in imaging studies. Additionally, it is helpful to examine
the blood clearance profile for any nanoparticles under investigation, since this will
influence nanoparticle delivery to both the target of interest and other locations.
There are a number of approaches to assessing nanoparticle concentrations in
vitro and in tissue or blood samples. They range from direct and quantitative methods,
such as radiolabeling, to indirect and qualitative surrogates, like the rate of tumor growth
1

following nanoparticle administration. The nanoparticle detection technique chosen by
the investigator is influenced by a number of factors including convenience, cost, and
level of detail required. Ideally, every evaluation of nanoparticle performance would
include quantitative and absolute determination of nanoparticle particle concentration at
the site of pathology, in off-target locations, and in the blood. However, the gold standard
for such measurements (radiolabeling) can be inconvenient for many investigators, due to
the special handling requirements of radioactive materials and quarantine considerations
of exposed animal subjects. Consequently, it is common for investigators to rely on semiquantitative measurements such as whole-animal and ex vivo fluorescence measurements.
A convenient and cost-effective alternative to radiolabeling that provides quantitative
measurements of biodistribution and blood clearance could make these data more
accessible to nanoparticle investigators.
Inherent in any nanoparticle study is also the comparison of delivery between two
or more formulations. For example, a passive targeting study might seek to optimize
some nanoparticle property (such as size, shape, charge, surface coating, or elasticity),
which requires comparison of multiple formulations that vary across the property of
interest. Or an active targeting study might compare the actively targeted agent to a
negative control that lacks the targeting ligand. Conventionally, these comparisons would
be made by administering each agent in a separate cohort of animals. The major
drawback to this approach, however, is the large animal-to-animal experimental
variability of in vivo studies. A convenient way to compare agents while controlling for
subject-to-subject variability is to employ a ratiometric/multiplex approach, whereby two
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or more agents are administered simultaneously to a single subject, and a “signal” from
each one can be independently resolved.
Even when radiolabeling is used to trace a nanoparticle’s biodistribution and
blood clearance, it is usually only feasible to examine one nanoparticle formulation in a
single sample or animal. It is possible to employ a ratiometric approach with
radiolabeling, using gamma emitters with resolvable energies9 or a combination of
gamma counting and scintillation,10 but physical restrictions of energy resolution
ultimately limit the number of compounds that can be simultaneously investigated.
Herein, we have sought to streamline the evaluation of sets of distinct
nanoparticle formulations, in vitro and in vivo, with the use of a quantitative and
multiplex assay for nanoparticle detection. Specifically, we have developed a method
whereby the concentration of superparamagnetic iron oxide (SPIO) nanoparticles can be
quantitatively determined using inductively coupled mass spectrometry (ICP-MS) of a
lanthanide metal tracer incorporated into the nanoparticle. Importantly, the concentration
of each lanthanide metal can be determined independently of other lanthanides present in
the sample. Therefore, it is possible to simultaneously administer multiple SPIO
formulations, with distinct physicochemical properties, to a single animal subject and
orthogonally assess their blood clearance, biodistribution, and passive delivery to a tumor
xenograft (Chapter 2). Investigation into the versatility of this system found that it could
be easily extended to a number of other commonly used imaging and therapeutic
nanoparticle constructs, such as liposomes, polymersomes, dendrimers, and gold
nanoparticles (Chapter 3). The technique was then applied to compare the active targeting
capability of SPIO formulations directed against distinct tumor markers (Chapter 4).
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Finally, a novel pH-sensitive SPIO nanoparticle was engineered for the detection of
acidic tumor microenvironments, and the ICP-MS based method was used to evaluate its
performance in vivo (Chapter 5). In this chapter, extensive background is provided on the
mechanisms of active and passive nanoparticle delivery, pH mediated delivery and
imaging, commonly used nanoparticle platforms, and typical methods of nanoparticle
detection and imaging in vivo.

1.2 Background
1.2.1 Passive and Active Targeting of Nanoparticle Platforms
1.2.1a Overview
As a nascent tumor develops, it will reach a stage in which the nutrient and waste
exchange through its local vasculature is insufficient to sustain its accelerated growth
profile.11 Thereafter, the tumor initiates the process of angiogenesis, in order to form new
blood vessels and allow for continued growth. Often these rapidly generating blood
vessels possess an abnormal basement membrane and an increased density of pericytes
associated with the proliferating endothelial cells.12 Consequently, the tumor neovasculature exhibits an increased level of permeability to macromolecular components.
Additionally, actively growing tumors often have disorganized and disrupted lymphatic
vessels, resulting in poor lymphatic drainage and impaired clearance of material from the
tumor interstitium.11 This combination of leaky vasculature and inefficient lymphatic
drainage results in a phenomenon known as the enhanced permeability and retention
(EPR) effect. EPR is a driving force for nanoparticles to preferentially accumulate in
4

regions of malignancy and is consistently exploited in studies of nanoparticle-based
imaging and therapeutic agents. Tumor accumulation derived solely from the
nanoparticle’s blood residence time and the EPR effect is commonly referred to as
passive targeting. Methods to improve nanoparticle tumor delivery, through specific
interactions with malignant cells or extracellular components, are termed active targeting.
Figure 1.1 depicts tumor delivery by the EPR effect and further enhancement through
active targeting.

Figure 1.1 Schematic of the enhanced permeability and retention (EPR) effect (passive
targeting) followed by nanoparticle binding to tumor cell receptor (active targeting)13

5

1.2.1b Passive Targeting
Passive targeting of nanoparticle formulations is their preferential, but nonspecific, accumulation at a tumor site secondary to the EPR effect. Even with a highly
permeable tumor vasculature, many passes through the circulation are required in order
for a large amount of nanoparticles to extravasate at the tumor. Therefore, a central
component of passive delivery is the design of nanoparticles with long in vivo circulation
times. One major obstacle to passive tumor delivery is the reticuloendothelial system
(RES), also commonly known as the mononuclear phagocyte system (MPS), which
efficiently clears nanoparticulate material from blood circulation.14 Accordingly,
nanoparticle formulations must be engineered to minimize interaction with the cells of
the RES. It is known that many properties of a nanoparticle (e.g. size, shape, surface
charge, hydrophilicity, and specific coating material) all influence the nanoparticle’s
interaction with blood and cellular components, thereby affecting circulation time. 15
The hydrodynamic diameter of a nanoparticle has a very strong influence on
circulation time and passive nanoparticle delivery.16 Specifically, nanoparticles smaller
than 5 nm are under the renal filtration threshold and are very rapidly cleared from
circulation. Blood circulation time and passive delivery by EPR is usually optimized for
nanoparticle sizes in the 10 – 100 nm range, where interaction with the RES is
minimized. Once the nanoparticle size begins to exceed 100 nm, interaction with the RES
increases again and extravasation through capillary fenestrations becomes impaired.17
Also critically important to nanoparticle circulation time and passive tumor
delivery by EPR is surface charge. Previous studies have demonstrated that prolonged
blood circulation, and therefore, optimal tumor delivery is achieved with nanoparticles
displaying a neutral to mildly negative surface charge.14,

18

When the surface charges
6

becomes overly negative, excessive association with phagocytic cells of the
reticuloendothelial system (RES) decreases circulation time,14,

18

and it has been

commonly reported that positively charged nanoparticles are cleared very rapidly due to
local electrostatic interactions near the injection site 19.
Specific properties of the nanoparticle coating material (e.g. hydrophilicity) also
influence nanoparticle circulation time. Since many groups have demonstrated that
incorporation of polyethylene glycol (PEG) into the surface of nanoparticles helps avoid
opsonization and increases circulation times,15,

20, 21

nanoparticle PEGylation is a very

popular method to impart in vivo stealth properties.22 Although PEGylation increases a
nanoparticle’s circulation time by minimizing its interactions with the RES, it may also
impair the nanoparticle’s ability to interact with tumor cells, thereby limiting uptake via
endocytic pathways.

23, 24

This potential drawback also must be considered when

designing nanoparticles for active targeting studies, so as not to have the nanoparticle’s
PEG brush mask or bury the active targeting ligand.

1.2.1c Active Targeting Strategies
Active targeting is a nanoparticle delivery strategy whereby affinity ligands on the
agent’s surface bind to specific receptors or biomarkers within the tumor. It is important
to note that successful active targeting still relies on efficient extravasation of the
nanoparticles through the permeable tumor endothelium. Therefore, the nanoparticle’s
physicochemical properties, which influence blood circulation and passive delivery by
the EPR effect, are still critically important in the design of actively targeted
nanoparticles. Once delivered to the tumor, however, actively targeted agents possess
several key advantages. While completely passive targeting is dependent on poor
7

lymphatic drainage in order to achieve nanoparticle retention at the tumor site, active
targeting also exploits specific binding to tumor receptors.25 Thus, actively targeted
nanoparticles can accumulate at higher concentrations compared to passively targeted
formulations, which are more easily washed out of the tumor interstitial compartment.
Also, depending on the type and surface density of ligands on the nanoparticle, it
is possible for the actively targeted agent to be internalized once it becomes bound.26, 27
Unlike individual antibodies, nanoparticles have varying degrees of multivalency, which
further increases the likelihood of cellular internalization.28,

29

For drug delivery

applications with membrane permeable drugs, nanoparticle delivery to the interstitial
compartment can be sufficient to achieve a therapeutic dose. However, membrane
impermeable payloads, such as hydrophilic small molecules, proteins, peptides, or
nucleic acids, require the nanoparticle to deliver them into the cell. Also, when
nanoparticles are internalized within cells, they payload is more efficiently trapped within
the tumor region and cell surface becomes available for interaction with additional
nanoparticles, resulting in greater payload delivery to the tumor. For these reasons, active
targeting strategies, whereby nanoparticles are engineered to specifically bind to tumor
cells and become internalized, have the potential to enhance diagnostic and therapeutic
potential.

1.2.1d Specific Active Targeting Biomakers Examined
A number of actively targeted agents for diagnosis and treatment of cancer are
currently in clinical use and an even greater number are currently being investigated.
They range in scale from radiolabeled small molecules such as

18

F-fluorodeoxyglucose

for PET imaging of tumor metabolic activity,30 short peptide analogs like

111

In8

pentetreotide for neuroendocrine tumor imaging,31 to antibodies such as

131

I-anti-CD20

for treatment of recurrent B-cell lymphoma,32 to nanoparticle assemblies for magnetic
resonance imaging of tumors.33 Various specific receptors have been targeted including
folate,34 transferrin,35 EGFR,36 IL2,37 and many others. In addition to directly targeting
surface receptors on malignant cells, contrast agents have been developed for to detect
neovascularization38, 39 and apoptosis,40, 41 two phenomena associated with tumorigenesis.
In Chapter 4, three specific active targeting receptor/ligand pairs will be examined and
background on these is provided below:
HER2/neu Receptor and Affibody Ligand
Human epidermal growth factor receptor 2 (HER2/neu) is a surface receptor
tyrosine kinase involved in signal transduction pathways of cell growth and
differentiation.42 It is overexpressed in approximately 30% of breast cancers, where it
correlates with increased tumor aggressiveness and metastatic potential.43, 44 HER2/neu
may also be overexpressed in ovarian cancer,45 colorectal cancer,46 and aggressive forms
of endometrial carcinoma.47 For these reasons, HER2/neu was identified as a promising
target for tumor active targeting strategies, and an anti-HER2/neu monoclonal antibody
(trastuzumab, Herceptin) is used clinically in the treatment of HER2 positive breast
cancers.48 For nanoparticle active targeting, one very promising ligand for HER2
targeting is the HER2/neu affibody. Affibodies are an attractive class of alternative
scaffold proteins derived from a 58-amino acid portion of staphylococcal protein A.49
They possess a high degree of specificity (similar to antibodies) but have a smaller
molecular weight of approximately 6.6 kDa (similar to phage-derived peptides).50, 51 The
HER2/neu affibody has high specificity and pM affinity for the HER2/neu receptor, and

9

has been utilized for several nanoparticle-based studies, with a high degree of targeting
success.52-54

αVβ3 Integrin and Cyclic RGD Ligand
αVβ3 integrin serves as a receptor for extracellular matrix proteins with exposed
arginine-glycine-aspartate (RGD) motifs, including fibronectin, vitronectin, lamin, and
collagen.55-57 Integrin binding facilitates cellular migration along these matrix proteins of
the intercellular space and basement membrane.58,

59

It is expressed at low levels on

epithelial and mature endothelial cells, but is overexpressed on activated endothelial cells
associated with the neovascularization of tumors.60-62 Interestingly, in tumor xenograft
models αVβ3 integrin can be overexpressed both on the malignant cells, themselves, and
on host-derived proliferating endothelial cells.63 Therefore, synthetic cyclic RGD
containing peptides are an attractive candidate for active targeting of rapidly growing and
metastatic tumors. In fact, radiotracers based on cyclic RGD are being investigated for
radiotherapy of αVβ3 integrin positive tumors and imaging with single photon emission
computed tomography (SPECT) and positron emission tomography (PET).64-66
HSP47 and LDS Affinity Peptide
Heat shock protein 47 (HSP47) is a collagen binding protein belonging to the
serine protease inhibitor (serpin) family.67 Its expression is upregulated during a cellular
stress response to noxious stimuli including high temperature, heavy metal exposure, and
oxidative stress.68 HSP47 is overexpressed in a range of human cancers including oral
squamous cell carcinoma,69 gastric cancer,70 pancreatic ductal carcinoma,71 lung cancer,72
and colonic adenocarcinoma secondary to ulcerative colitis.73 The ligand chosen to target
HSP47 was a small peptide affinity ligand called “LDS”, based on its first three residues.
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LDS was derived from phage display panning against HSP47 and its binding to HSP47
positive tumor cells has been demonstrated.74

1.2.2 pH Imaging
Besides

passive

nanoparticle

delivery

(Chapter

2)

and

conventional

receptor/ligand based active targeting (Chapter 4), another increasingly popular strategy
is to target local metabolic changes associated with malignancy. In Chapter 5, we present
a novel pH-sensitive SPIO nanoparticle and evaluate its performance in vivo using a
lanthanide tracer. Accordingly, this section contains background information on tumor
pH alterations and pH imaging agents.

1.2.2a Tumor pH Alterations
In healthy mammalian tissues, acid-base homeostasis is maintained through a delicate
balance between acid production and removal. A pH regulatory mechanism is necessary
since acids are an invariable side product of both aerobic and anaerobic metabolism. In
the case of aerobic metabolism, sugar is metabolized to pyruvate, which in the presence
of oxygen is oxidized by the mitochondria to CO2 and H2O. CO2 is then transported
outside the cell where it is hydrated by carbonic anhydrases to form bicarbonate plus a
free proton, H+. In the case of anaerobic metabolism, i.e. in the absence of oxygen,
pyruvate is reduced to lactic acid and is subsequently exported from cells. Once in the
extracellular space, acids diffuse from the site of production to the blood, where they are
buffered by an open and dynamic CO2/HCO3- system.
Although the physiological mechanisms responsible for stabilizing the intra- and
extracellular pH are quite robust, many pathological conditions including cancer have
11

been associated with an increase in tissue acidity. This sub-physiological pH is thought
to arise from the increase in glycolysis, seen in nearly all invasive cancers (even under
aerobic conditions), and poor perfusion, due to a chaotic and heterogeneous
microvasculature in the tumor microenvironment. Interestingly, it has been observed that
even in the absence of glycolysis the extracellular pH can still reach values as low as
6.65;75 however, it has been hypothesized that elevated glycolysis may still be needed for
“hyperacidity”.76 Numerous studies have shown that the extracellular pH of human and
animal tumors can reach values approaching 6.0, which is likely not possible without
elevated glycolysis.77,

78

The critical importance of identifying pathologies with sub-

physiologic pH stems from studies that show low pH stimulates in vitro invasion and in
vivo metastases.79,

80

This has led to the development of numerous techniques and

imaging strategies for measuring pH in vivo.

1.2.2b Absolute pH Imaging
In recent years, numerous methods have been developed that allow for the noninvasive assessment of tissue pH, most of which are based on magnetic resonance.81 One
common technique relies on the

31

P MR resonance of phosphate.82 Since intracellular

inorganic phosphate (Pi) concentrations are higher than extracellular concentrations and
the intracellular volume fraction is greater than 50%, the chemical shift of endogenous Pi
is generally thought to reflect intracellular pH. Extracellular pH of tumors can also be
separately measured using exogenous agents such as 3-aminopropylphosphate (3-APP).83
3-APP is a non-toxic, membrane impermeant compound that has a pH-dependent
chemical shift, 1 ppm per pH unit, in the physiological range.

12

Exogenous agents have also been developed with pH-sensitive
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F resonances.84,

85

The almost complete lack of endogenous 19F resonances in normal tissues combined with
the high gyromagnetic ratio and large chemical shift dispersion of

19

F compounds has

been reported to result in improved signal-to-noise and resolvable pH-dependent
chemical shifts, compared with
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P MRS of 3-APP.

However, drawbacks of

19

F

approaches include the instability of fluorinated compounds and the inability to
simultaneously measure other metabolic compounds.81
Since the 1H nucleus offers the highest inherent sensitivity for MR detection and
because it is possible to image the spatial distribution of tissue pH with pH-sensitive 1H
resonances, numerous groups have employed imidazole-based compounds such as IEPA
to measure pH in vivo.86-89 IEPA is non-toxic, membrane impermeant, and has few
interfering background resonances. The drawback of using IEPA, however, is that the
chemical shift is only 0.7 ppm over the entire titration range, which generally means that
imaging must be conducted under (high) field strengths that are not available in most
clinics. An alternative 1H MR imaging method exploits the pH-dependent magnetization
transfer (CEST) between bulk phase water and either endogenous protein amide groups
or exogenous probe molecules.90,

91

pH-dependent gadolinium-based relaxation agents

can also be used;92-94 however, both of these approaches require an accurate
determination of probe concentration, which is difficult to achieve in vivo.
Recently, magnetic resonance imaging of pH has also been performed using
hyperpolarized 13C-labeled bicarbonate.95 Specifically, pH was imaged from the ratio of
signal intensities of hyperpolarized bicarbonate (H13CO3-) and
distribution of

13

13

CO2.

The spatial

CO2 and H13CO3- was imaged in a mouse tumor model with an image
13

resolution of 16 x 16 voxels, each measuring 2 x 2 x 6 mm, on a 9.4T MR. This clearly
represents another step towards the ultimate goal of imaging pH in human clinical
pathologies; however, advancements must still be made to improve the spatiotemporal
resolution of MR spectroscopy on 1.5T scanners before these techniques are adopted for
routine clinical use.

1.2.2c Relative pH Imaging
A complimentary approach to absolute pH imaging MRS (where the pH is
determined by the chemical shift of the probe) or CEST (where changes in pH influence
the chemical exchange kinetics) is to detect regions of relatively abnormal pH by
designing agents that preferentially accumulate in these regions. That is, the identity of
the signal is not influenced by pH, but the biodistribution of the agent is influenced by
pH. In this respect, such an agent has much in common with a classic receptor/ligand
actively targeted molecule; the agent washes into the tumor through the enhanced
permeability of the tumor vasculature and then is preferentially retained at the tumor site
through pH mediated alterations in the nanoparticle’s physicochemical properties.
One such targeting moiety is pH low insertion peptide (pHLIP).96-98 At neutral or
basic pH this peptide exists in equilibrium between an unstructured aqueous
conformation and a conformation bound to the surface of lipid bilayers. As pH falls
below 7.0, the equilibrium is directed towards a transmembrane helical conformation
such that the affinity of pHLIP for cell membranes is approximately 20 times higher at
low pH. Once inserted across a cell membrane at low pH, it can remain in place on the
order of days. This pH-sensitive peptide has subsequently been used to produce pH
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sensitive contrast agents. An optical agent consists of pHLIP directly conjugated to
fluorescent dye (e.g. Cy5.5), and has been used in animal models to detect tumors and
visualize tumor margins in mock surgical procedures.99 A PET agent was constructed by
pHLIP conjugation to 64CuDOTA. Studies using mouse xenografts of two human prostate
cancer cell lines demonstrated the PET agent avidly concentrated at the tumor site in a
pH dependent manner.100 Beyond pHLIP agents, recently, a pH sensitive MR contrast
agent has been reported that consists of magnetic nanoparticles encapsulated by PEGPAE diblock copolymer.101 The composite particle is stable in aqueous environments at
physiologic pH and higher, but upon exposure to pH less than 7.0, the PAE polymer
block is protonated, leading to destabilization of the construct and precipitation of the
magnetic nanoparticles in situ. Once micro-precipitation occurs at the tumor site, the MR
signal is amplified and diffusion of the agent out of tumor becomes more difficult.

1.2.3 Diversity of Nanoparticle Platforms and Properties
There are many different nanoparticle architectures, built from a wide array of
materials, possessing great variation across a range of physicochemical parameters. In
order to optimize nanoparticle characteristics, improve nanoparticle performance in
animal models, and identify specific agents to bring to clinical testing, a method allowing
convenient and quantitative detection of multiple agents in a single animal would be
valuable. Chapters 2 and 3 demonstrate how ICP-MS multiplex analysis can be adapted
to a wide range of nanoparticle platforms in vivo. Accordingly, background on these
specific nanoparticle constructs is provided in the following section.
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1.2.3a Superparamagnetic Iron Oxide (SPIO) Nanoparticles
SPIO nanoparticles typically consist of a magnetite (Fe3O4) and/or maghemite
(γFe2O3) iron core and a hydrophilic surface coating.33 In the presence of an external
magnetic field, the magnetic moments of the SPIO align with the field and enhance the
local magnetic flux. This effect allows them to influence both the longitudinal and
transverse relaxation of surrounding protons. While the iron oxide core is responsible for
generating magnetic contrast, the hydrophilic coating is used to improve the solubility,
biocompatibility, and stability of the iron oxide nanoparticles. A variety of biocompatible
polymers have been employed as the coating, including PEG and PLGA, and
polysaccharides, such as dextran.33,

102

Varieties of surface modifications (including

attachment of targeting ligands) can subsequently be applied to SPIO, depending on the
particular application.

Figure 1.2. Illustration of dextran stabilized superparamagnetic iron oxide (SPIO), with
metal core in brown and dextran chains in blue.

Clinical use of SPIO nanoparticles as MR contrast agents began in the 1980’s.
Since SPIO nanoparticles often exhibit uptake in the organs of the RES, they are well
suited to aid in delineation of both primary tumors of the liver103 as well as metastatic
16

lesions.104 Furthermore, since SPIO nanoparticles gain access to the lymphatic drainage
of tumors and lymph nodes contain a high number of phagocytic cells, SPIO can be used
to survey for lymph node metastases, which aids in cancer staging and therapeutic
planning.105-107 Although this application is promising, the ultimate goal is to utilize SPIO
nanoparticles for cellular and molecular imaging applications, allowing for the detection
of malignancies prior to metastasis.
Detection of non-RES primary tumors with SPIO nanoparticles is currently
impeded by the sensitivity limitations associated with many MR contrast agents. There
are numerous approaches for improving SPIO nanoparticle sensitivity, including the
optimization of SPIO magnetic properties, SPIO targeting methods, MR pulse sequences,
MR hardware, and signal post-processing techniques. For example, incorporation of
hetero-metals such as manganese into the iron core108-110 has been shown to increase
relaxivity, and loading multiple SPIO into single nanovesicles111-113 increases the signal
of each individual particle. Other groups have used a self-amplification approach114 to
boost the local concentration of SPIO at sites of interest, while others are developing
activatable probes,115, 116 in order to increase contrast by lowering background signal.

1.2.3b Liposomes and Polymersomes
Liposomes are small artificial bilayer vesicles composed of either naturally
occurring lipids or a number of commercially available synthetic products. The natural or
synthetic phospholipids have a hydrophobic lipid “tail” and a polar “head” constructed
from various glycerylphosphate derivatives. Due to their amphiphilic nature, when
phospholipid molecules are dispersed in aqueous media they can self-assemble into
spherical, closed structures consisting of an aqueous core surrounded by a highly ordered
17

phospholipid bilayer. Consequently, liposomes can encapsulate hydrophilic compounds
in their aqueous cores and intercalate hydrophobic compounds in their lipid bilayers.
Liposomes vary widely in size, number of lamellae, surface charge, permeability,
and bilayer rigidity, depending on the preparative technique, synthetic conditions, and
types of lipids used. Their sizes range over three orders of magnitude, from tens of
nanometers to tens of micrometers. These structural parameters affect the behavior of
liposomes both in vitro and in vivo. Therefore, it is critical to carefully select the
liposome constituents and preparative technique for the intended application. For
example, conventional liposomes are rapidly cleared from the circulation by the
phagocytic cells of the RES. Therefore, for in vivo applications, steps such as pegylation
or steric stabilization, must be taken to prolong circulation time.117, 118 The coat has been
shown to inhibit serum protein binding on the liposomal surface, thereby reducing RES
sequestration, complement activation, and destabilization of the liposomal membranes.
Incorporation of cholesterol into the phospholipid membrane has also been shown to
improve liposome stability.119
Polymersomes, by contrast, are self-assembled nanovesicles composed of
amphiphilic synthetic block copolymers. Most commonly polyethylene oxide (PEO) is
used as the hydrophilic block. This creates a relatively intert, brush-like outer shell,
which imparts “stealth” characteristics to the polymersomes and allows them to
effectively

avoid

the

reticuloendothelial

system.120

Compared

to

liposomes,

polymersomes are far more robust, have lower membrane permeability, greater stability,
and can be finely tuned through polymer selection to yield vesicles with diverse

18

functionality. Combined with their high stability, polymersomes have been found to
exhibit long circulation times and low toxicity.120
The improved stability of polyersomes largely stems from the higher molecular
weight of the diblock copolymers and the presence of a thick hydrophobic domain,
typically ~8-10 nm. This is significantly larger than the hydrophobic domain of most
liposomes, which are typically ~3 nm in thickness.121 However, increased membrane
thickness generally leads to decreased membrane fluidity and deformability, bringing the
mechanical properties of polymersomes closer to viral capsids than liposomes.
Both liposomes and polymersomes are attractive platforms for imaging and drug
delivery because payloads can be encapsulated within the vesicles and delivered to sites
of interest. Furthermore, sequestering the payload from direct exposure to the blood can
prevent it from being damaged by circulating enzymes or causing excess toxicity. For
example, when liposomes are used to encapsulate imaging agents, they help overcome
the rapid clearance, non-specific cellular interaction, and toxicity of free contrast, all of
which result in images of diminished contrast and resolution.122 Polyermersomes, as well,
are easily transformed into imaging agents through the encapsulation of hydrophilic
contrast material (e.g. Gd-DTPA, fluorescent dyes) within the aqueous core and/or
hydrophobic fluorescent dyes within the membrane.
Nanovesicles can also be combined with active targeting strategies to direct
encapsulated drugs or contrast agents to specific organs or pathologies. Targeted delivery
of liposomes in vivo has been achieved by covalent and non-covalent coupling of sitedirecting ligands (such as monoclonal antibodies, proteins, vitamins, peptides, and
glycolipids) to the surface of liposomes.123 For example, PEG-shielded liposomes
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functionalized with cyclic RGD have been used to target the antivascular agent
combretastatin A4 to tumor vasculature.124 The exterior surface of polymersomes can
also be readily functionalized with biologically active ligands for targeting
applications.125

1.2.3c Dendrimeric Nanoparticles
Dendrimers are highly uniform, spheroid polymeric nanostructures that
repeatedly branch outward from an inner mulitmeric core. They are usually produced in
an iterative sequence of reaction steps, where each generation results in an exponential
increase in molecular weight and a geometric increase in volume.126 For imaging
applications, PAMAM dendrimers are most commonly used, and they range in size from
about 1 nm to just over 13 nm, depending on the generation.127 PAMAM dendrimers
possess an ethylenediamine core and display amino groups on the surface, which provide
convenient reactivity for surface modifications.128-131 For drug delivery applications, it is
also possible to encapsulate molecules inside interior cavities of a high generation
dendrimer.132
Dendrimers possess many structural parameters, including base material, size,
shape, branching, length, and surface functionality,133 that can all affect the dendrimer’s
performance as an imaging or therapeutic platform. For example, smaller generation
dendrimers are subject to rapid renal elimination, with blood half-lives of only a few
minutes.134 Those with charged or hydrophobic surfaces are also rapidly cleared from
circulation, but tend to accumulate in the liver.135 However, dendrimers with a neutral or
hydrophilic surface, such as PEG, can exhibit blood half-lives reaching many hours.135
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1.2.3d Gold Nanoparticles
The use of gold nanoparticles in biological applications began in 1971 when
Faulk and Taylor invented the immunogold staining procedure for electron
microscopy.136 Gold nanoparticles which are typically sized between 0.5 and 250 nm,
have been prepared in a wide variety of shapes including spherical, 137, 138 rods, 139, 140 and
barbells.141 Gold has also been used as a thin shell-coating for a dielectric core.142 Their
straightforward synthesis, excellent stability, and the ease of functionalization with
targeting ligands have permitted the use of gold nanoparticles in both imaging and
therapeutic applications.
Gold nanoparticles can be used with multiple imaging platforms for in vivo
molecular imaging. For instance, gold nanoparticles complexed with a thiol-PEG coating
and targeted with anti-EGFR single chain antibody fragments have been used to target
tumors in vivo using surface enhanced Raman spectroscopy (SERS).143 Gold
nanoparticles are also being investigated as X-ray and computed tomography (CT)
contrast agents. Recently, 1.9 nm gold nanoparticles, administered intravenously in a
mouse tumor model, allowed for high resolution imaging of the tumor, blood vessels, and
kidneys.144 Since gold nanoparticles exhibit greater X-ray attenuation than iodine-based
contrast agents, it was even possible to visualize microvasculature and neovasularization
within the tumor. Beyond imaging applications, gold nanorods are also being investigated
as therapeutic photothermal agents. Specifically, small axial diameter nanorods, delivered
to an animal tumor, serve as highly efficient absorbers of near infrared light.145 When
short IR laser pulses are applied to the tumor volume, the laser energy is converted to
heat, leading to ablation of the lesion.146
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1.2.4 Detection and Imaging Modalities
There are numerous modalities to detect, quantify, and image nanoparticle
formulations in vitro, in vivo, and ex vivo. Each method has its own unique advantages
and disadvantages, which compels the investigator to select a modality that best suits the
particular application. A partial list of detection and imaging modalities, along with their
strengths and weaknesses is provided in table 2.1.
Table 1.1. Common Nanoparticle Detection and Imaging Modalities
Method

Advantages

Disadvantages /
Limitations

Quantitative

Multiplex

Nuclear
PET/SPECT

Very High
Sensitivity,
Functional
Information

Poor Resolution, Ionizing
Radiation, Agent
Requires EHRS Handling

Yes

Possible
2-3

Optical /
Fluorescence

High Sensitivity,
Ease of Use

Lower Resolution, Altered
or Prevented by Tissue
Type/Depth

Semi

Yes

MR / MRS

High
Resolution,
Anatomical and
Functional
Information

Low Contrast Sensitivity,
Long Scan Time, Low
Temporal Resolution,
Expensive

Yes*

Possible

Mass
Spectrometry

High Sensitivity

Ex Vivo Only

Yes

Yes

CT / X ray

High
Resolution,
High Temporal
Resolution

Very Low Contrast
Sensitivity, Ionizing
Radiation

Yes*

Possible

Ultrasound

Widely
Available, High
Temporal
Resolution,
Inexpensive

Lower Resolution,
Contrast is Intravascular
Only, Altered or
Prevented by Tissue
Type/Depth

No

No

Histology

High
Resolution,
Functional and
Structural
Information

Ex Vivo, Sample
Preparation

Semi

Yes

* These modalities provide quantitative data, but calculation of exogenous agent
concentration is usually semiquantitative
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1.2.4a Nuclear and Radiolabel Detection and Imaging
The “gold standard” of pharmacokinetic and pharmacodynamic measurements is
the use of radionuclide tracers. Radiolabeling provides absolute quantitation of tracer
concentrations and very high (pM) sensitivity.147 Although there are several mechanisms
of nuclear decay (e.g. alpha, beta, gamma, positron emission, electron capture, isomeric
transition, and internal conversion), radiotracer signals largely fall into two categories:
gamma or beta emitters. Gamma radiation passes through soft tissue samples with little
attenuation and can be quantified with minimal sample preparation using a gamma
counting instrument. Beta particles, however, require indirect counting, which
necessitates more sample preparation. Specifically, the sample is dissolved in a liquid
scintillation solution, containing a scintillant that absorbs the beta particle’s energy and
emits light for detection.
The earliest experiments studying the in vivo biodistribution and clearance of
nanoparticle formulations relied on radiolabeling. The long-lived radionuclides 3H,
and

125

14

C,

I were used to trace the activity of small molecule payloads incorporated into

nanoparticles.148-150 More recently, the γ emitters

111

In and

99m

Tc have gained popularity

as nanoparticle radiolabels, since they have relatively mild labeling procedures and can
be used for in vivo imaging (SPECT) followed by ex vivo measurements of
biodistribution. For PET imaging of nanoparticle formulations,

64

Cu is most commonly

used.
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Table 1.2. Common Radionuclides for Nanoparticle Investigation
Radionuclide
1

H

14

C

Decay Mode

Half Life

β

12.35 years

β

5730 years

18

F

β+

109.77 minutes

32

P

β

25.4 days

Cu

β+

12.7 hours

99m

Tc

γ

6.00 hours

111

In

γ

2.83 days

64

125

I

γ

60.14 days

131

I

β

8.02 days

One major benefit of the metal radiotracers is the versatility available for
incorporating the tracer into the nanoparticle formulation. Direct radiolabeling can be
accomplished through reduction of disulfide bonds followed by introduction of the
metal.151, 152 More typically, a chelator (e.g. DTPA,153, 154 HYN-IC,155, 156 or DOTA157) is
used to bind the metal. The chelator may be covalently conjugated to the surface of the
nanoparticle, face the aqueous core,158, 159 or be buried within a hydrophobic domain160,
161

(e.g. bilayer of a liposome or core of a micelle). For vesicular structures such as

liposomes and polyersomes, a preformed metal-chelator complex can be encapsulated
within the aqueous core.162,

163

It is possible to incorporate the chelator into the

monomeric/block co-polymer material prior to nanoparticle assembly,164 covalently
conjugate the chelator to a previously assembled nanoparticle,165 or non-covalently attach
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a chelator functionalized moiety (e.g. protein or peptide) to the nanoparticle surface.166
Addition of radiolabels to nanoparticles may have a minimal or significant impact on the
agent’s pharmacokinetics, depending on the location of the radiolabel within the
nanoparticle (i.e. core versus surface) and the fractional increase in nanoparticle size
upon radiolabeling.
The major limitation to radiolabeling, for the purposes of nanoparticle
characterization, is the relative lack of multiplexing capability. A two-label ratiometric
approach is well established using a low and high energy gamma emitter (e.g.
111

125

I and

In).9, 167 A triplex assay is conceivable by adding a beta emitter detected separately by

scintillation, but would then require separate preps and measurements to obtain the
information. Higher order multiplexing (achievable by optical instrumentation in vitro or
ICP-MS ex vivo) is unlikely to be feasible. Another, smaller consideration is the special
handling requirements for radioactive material and animals. Laboratory handling of
radionuclides is by no means “difficult”; but its inconvenience decreases the frequency of
its use, and an alternative method of absolute quantification of nanoparticle concentration
in biological samples, without radioactivity, may lead more investigators to acquire such
data.

1.2.4b Optical and Fluorescence Detection and Imaging
Optical and fluorescence detection of nanoparticles is arguably the most
convenient and widely used approach. Fluorescence is usually imparted to a nanoparticle
by incorporation of either an organic dye or inorganic fluorophore (i.e. quantum dot).
Many different small molecule organic fluorophores, spanning the visible and infrared
spectrum, have been successfully used with nanoparticles, including: fluoresceins,
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cyanines, rhodamines, and specific commercial dye lines like Alexa Fluor, DyLight, and
BODIPY. The fluorophores can be incorporated by covalent conjugation or encapsulation
within an aqueous or hydrophobic core. The labeled nanoparticles can then be imaged at
the whole animal level or in ex vivo specimens. Multiplexing of fluorophores with
resolvable excitation and emission spectra is possible, as evidenced by multi-color flow
cytometry.168 However, applying this principle at the tissue, organ, and animal level is
more difficult since a large region of the visible spectrum is unsuitable for fluorescence
measurements in complex or thick samples (see below).
Perhaps the biggest limitation of fluorescence detection and imaging of
nanoparticles are issues associated with tissue penetration and interference. Specifically,
both the incident excitation radiation and the emitted signal are subject to attenuation as
they pass through biological tissue. Since light scattering decreases as 1/λ4 and photon
absorption by endogenous oxygenated and deoxygenated hemoglobin reaches a minimum
in the near infrared (NIR) spectral window,169 tissue penetration is wavelength dependent
– with longer wavelengths suffering less attenuation than shorter wavelengths.
Nevertheless, even the brightest and most red-shifted organic fluorphores are limited to
approximately 5 cm of tissue penetration.170 This distance limit is suitable for small
animal work, but is limiting for human applications other than those involving exposed
tissue (e.g. superficial soft tissue and skin,171 fluorescence assisited surgery,172 or
endoscopic methods).173
Another significant drawback of fluorescence detection of nanoparticles is its
restriction to semi-quantitative measurements. That is, the concentration of the
fluorophore, and therefore the nanoparticle, cannot be calculated from its signal, due to a
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number interfering variables present in biological samples. For example, the peak
excitation/emission wavelength, extinction coefficient, and quantum yield can vary with a
number of parameters including local chemical environment, exposure time, and
temperature. Fluorescence quenching, either from other molecules of the same
fluorophore or endogenous absorbers, leads to significant non-linearity. Tissue thickness,
density, composition, and auto-fluorescence also all influence signal, even with ex vivo
sampling.

1.2.4c Magnetic Resonance Detection and Imaging
Magnetic resonance approaches are capable of obtaining an extremely diverse
array of structural and functional information in vivo (see also the pH imaging section
above). Generally speaking, the functional information is often extracted in one of three
ways. First, in magnetic resonance spectroscopy (MRS) the chemical shift of a particular
resonance may change with variations in some physiologic parameter. In this manner, the
varying
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P resonance of 3-APP is used to deduce extracellular pH.83 Secondly,

alterations in the metabolic environment of tissues can be deduced using the ratio of the
signals from two or more metabolites in an MRS study. For example, studies have found
that a high choline / N-acetyl aspartate is commonly observed in brain tumors.174 Thirdly,
chemical exchange saturation transfer (CEST) measurements detect the transfer of
magnetization between two pools in chemical exchange, leading to signal amplification,
signals that can be “switched” on and off, and detection of physiologic stimuli by
alterations they cause in the CEST effect.175
Measuring the absolute concentration of a particular resonance or metabolite with
magnetic resonance methods is much more difficult, although significant progress has
27

been and continues to be made for endogenous metabolites.176 With regard to
determination of nanoparticle concentrations, however, absolute quantification is not yet
possible. Since the concentration of nanoparticles delivered in vivo is not very large
compared to the sensitivity of MR methods, direct detection of a nanoparticle’s resonance
is difficult. Instead, nanoparticles imaged by MR are usually detected indirectly through
their interaction with bulk water protons. For example, Gd3+ can be incorporated into
nanoparticles with metal chelators, much the same as metal radionuclides can.177 The
gadolinium ion’s seven unpaired electrons provide a conduit through which bulk water
protons can transfer energy, allowing their longitudinal relaxation rate to be increased.
This in turn leads to a stronger (brighter) signal on T1-weighted images for voxels
containing the nanoparticle. SPIO nanoparticles contain iron oxide crystals, which
generate disturbances in the local magnetic field surrounding the nanoparticles. This in
turn causes accelerated de-phasing of the bulk water magnetization following a 90°
radiofrequency pulse, which leads to a weaker (darker) signal on T2-weighted images.
With SPIO or Gd3+ doped nanoparticles, it is possible to estimate nanoparticle
concentration using a calibration curve with a tissue phantom. However, accurate
absolute quantification is difficult since many specific properties of the tissue and pulse
sequence will influence the signal obtained. Furthermore, detection by this method is not
amenable to multiplexing.

1.2.4d Inductively Coupled Plasma – Mass Spectrometry (ICP-MS)
Detection
ICP-MS is an analytical method allowing for the rapid and sensitive (1 ppt to 1
ppb) detection of a wide range of metal species in a sample. The basic instrument design
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places a mass spectrometer downstream of an inductively coupled plasma source. The
ICP is generated by introducing a small number of electrons into an argon gas stream and
then applying radiofrequency radiation to cause rapid oscillation of the free electrons.
Collisions between the electrons and argon atoms result in ionization, producing Ar+ and
additional electrons. A steady state is quickly reached, resulting in electro-neutral plasma
with a temperature significantly greater than a chemical flame.
In order to analyze a sample containing complex material, such as blood or tissue,
the material must first be digested with nitric or hydrochloric acid to produce a more
homogenous liquid. The sample is then nebulized and introduced into the plasma stream,
where the extremely high temperature leads to atomization, and subsequent ionization, of
the material. The metals ions of the sample are then fed from the plasma into a
conventional mass spectrometer (usually quadrupole, or less frequently, time of flight).
Importantly, the concentration of each metal ion being investigated can be simultaneously
acquired with a single measurement.
ICP-MS multiplexing is already being successfully applied to in vitro
immunoassays.178 Specifically, a polymer tag containing multiple lanthanide metal
chelates is attached to the Fc portion of antibodies.179 In this manner, each specific
antigen/antibody is associated with a specific lanthanide metal. In vitro multiplex analysis
has been applied for a variety of cell surface biomarkers180,

181

and growth and

transcription factors in cell lysates.178 Very recently (May 2011) the massively-parallel
nature of ICP-MS multiplex analysis was demonstrated with simultaneous “mass
cytometric” analysis of more than 30 cell markers.182
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Another recent development in ICP-MS instrumentation is laser ablation LA-ICPMS, which offers three considerable advantages over conventional ICP-MS. First, the
original sample can be analyzed directly (i.e. without chemical digestion) by ablating the
sample with a pulsed laser beam and sweeping the aerosol directly into the plasma.
Secondly, LA-ICP-MS can be conducted with much smaller amounts of material.
Specifically, micrograms samples can be analyzed, versus milligrams for conventional
ICP-MS (i.e. the entire sample is microgram quantity; the amount of lanthanide need only
be parts per billion concentration within the sample). Thirdly, the laser pulses can be
scanned across a solid sample, allowing for a mass “image” to be generated for an organ
or tumor with heterogeneously distributed nanoparticles.
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Chapter 2: Development of ICP-MS Analytical Method to Quantify
SPIO Nanoparticle Clearance and Organ Concentration
2.1 Abstract
Recent advances in material science and chemistry have led to the development of
nanoparticles with diverse physicochemical properties, e.g. size, charge, shape, and
surface chemistry. Evaluating which physicochemical properties are best for imaging and
therapeutic studies is challenging not only because of the multitude of samples to
evaluate, but also because of the large experimental variability associated with in vivo
studies (e.g. differences in tumor size, injected dose, subject weight, etc.). To address this
issue, we have developed a novel lanthanide-doped nanoparticle system and analytical
method that allows for the quantitative comparison of multiple nanoparticle compositions
simultaneously. Specifically, SPIO with a range of different sizes and charges were
synthesized, each with a unique lanthanide dopant. Following the simultaneous injection
of the various SPIO compositions into tumor-bearing mice, inductively coupled plasma
mass spectroscopy (ICP-MS) was used to quantitatively and orthogonally assess the
concentration of each specific SPIO composition in serial blood samples and the resected
tumor and organs. This approach provides a simple, cost-effective, and non-radiative
method to quantitatively compare tumor localization, biodistribution, and blood clearance
of more than 10 nanoparticle compositions simultaneously, removing subject-to-subject
variability.
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2.2. Introduction
Over the past decade, interest in the development of nanoparticles for clinical
applications, such as diagnosis and drug delivery, has increased exponentially, along with
the number of specific nanoparticle formulations reported in the literature.1-5 Given the
variety of nanomaterials from which they can be constructed, the array of
physicochemical properties they can possess, and the assortment of specific molecular
processes that can be targeted in vivo, the number of potential nanoparticle combinations
is truly astronomical.
For most nanoparticle applications, a crucial research question is how much of the
nanoparticle formulation (and thus imaging or therapeutic payload) reaches the tissue of
interest. However, since determining this information directly and quantitatively is often
impractical, indirect or semi-quantitative methods are usually employed. For example,
relative nanoparticle delivery may be inferred from fluorescence intensity, imaging
contrast, or alterations in tumor growth rate. However, since nanoparticle delivery is only
one of several variables affecting fluorescence intensity, imaging contrast, and tumor
growth rate, they cannot be assumed to represent nanoparticle delivery.
The “gold standard” for quantitative determination of biodistribution and blood
clearance is through incorporation of a radioisotope within the compound of interest.
Given the large number of radioisotopes to choose from, a compound can usually be
radiolabeled by replacement of a stable isotope, ensuring the label has minimal impact on
the behavior of the compound. Radiolabeling also has the advantage of being very
sensitive. However, one major drawback to the use of radiolabeling is the special
handling and containment protocols required when working with radioactivity. Therefore,
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a quantitative approach that does not require special laboratory precautions could make
measurements of clearance and biodistribution more accessible.
Another, perhaps even more important, research question is how does one
nanoparticle’s delivery to a tissue of interest compare to another’s. Whether comparing a
new investigational agent to a negative control or optimizing a specific set of
nanoparticles, such data are indispensable for development of better nanoparticle
formulations and progression to clinical use. Beyond the difficulties of obtaining
quantitative data for an individual nanoparticle’s biodistribution, there are also problems
using this data to compare nanoparticle formulations due to the large experimental
variability of in vivo studies. A convenient way to compare agents while controlling for
subject-to-subject variability is to employ a ratiometric or multiplex approach, whereby
two or more agents are administered simultaneously to a single subject, and a “signal”
from each one can be independently resolved. It is possible to employ a multiplex
approach with radiolabeling, using gamma emitters with resolvable energies6 or a
combination of gamma counting and scintillation,7 but physical limitations of energy
resolution ultimately limit the number of compounds that can be simultaneously
investigated.
In order to address these limitations, a method was designed that would allow for
the quantitative determination of biodistribution and blood clearance of multiple
nanoparticle formulations in a single animal (Figure 2.1). Specifically, lanthanide metals
were doped into the iron cores of superparamagnetic iron oxide (SPIO) nanoparticless.
Multiple lanthanide-labeled nanoparticles were then injected in individual animals
simultaneously. Inductively coupled mass spectrometry (ICP-MS) was then used to
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detect parts-per-billion (ppb) concentrations of the lanthanide metals, independent of one
another, in tissue and blood. Since lanthanide and other heavy metals (e.g. gold, silver,
etc.) do not naturally exist within animal subjects, the concentration of the lanthanide
metals unambiguously represents the concentration of its associated nanoparticle. This
“ICP-MS multiplex” approach should provide a sensitive and straightforward method for
quantitatively comparing the biodistribution and blood clearance of multiple nanoparticle
formulations simultaneously, without the disadvantages of radioactivity and subject-tosubject variability.

Figure 2.1 Schematic of the ICP-MS based multiplex method for determining biodistribution and blood
clearance. (A) Nanoparticles of varying physicochemical properties are combined into a single solution.
Each type of nanoparticle is associated with a unique lanthanide metal; either by encapsulation or chelation
(for example, the large and neutral particle contains Gd while the small and negative particle contains Ho).
The concentration of each lanthanide metal in the injected solution is measured by ICP-MS and the
combined solution is injected intravenously into the animal. (B) Blood samples are drawn at various times
post-injection and following the final blood draw, the animal is sacrificed and the tumor and other organs
are excised and rinsed in water. The blood and tissue samples are weighed and digested with nitric acid,
and then the concentration of each lanthanide metal is determined by ICP-MS.
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2.3 Materials and Methods
Synthesis of Dextran Stabilized Lanthanide Doped SPIO
Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran. 8 Briefly,
25 g of dextran T-10 (Pharmacosmos A/S, Holbaek, Denmark), was dissolved in 500 mL
dH2O and heated to 80°C for 1 hour. The solution was then allowed to cool to room
temperature and continued to mix overnight. Subsequently, a solution of 1.85 g FeCl3,
0.73 g FeCl2, and 0.125 g LnCl3•6H2O (Ln = Ho, Eu, Er, Sm, or Gd) in 25 mL dH2O was
prepared and decanted into the dextran solution. The combined solution was cooled on
ice and degassed with N2 for 90 min. While keeping the solution stirring on ice and under
N2, an automated syringe pump was then used to introduce 15 mL of concentrated
NH4OH to the solution over 5 hours. The resulting black viscous solution was removed
from the N2 atmosphere, heated to 90°C for 1 hour, cooled overnight, and centrifuged at
20,000 RCF for 30 minutes to remove large aggregates. Free iron, lanthanide, and
dextran were removed by diafilitration across a 100 kDa membrane and the Ln-SPIO
were brought to a final volume of ≈40 mL at 10 mg Fe/mL.
This 40 mL of dextran SPIO at an iron concentration of 10 mg/mL was then
combined with an equal volume of 10 M NaOH and mixed for 10 minutes. 80 mL of
epichlorohydrin was then added and the solution was vigorously stirred at room
temperature overnight. Epichlorohydrin crosslinks the dextran coating within the LnSPIO particle and chemically activates the dextran surface for conjugation. The solution
was then briefly centrifuged to allow phase-separation into an aqueous black SPIO layer
and a clear layer of unreacted epichlorohydrin, which was removed. The SPIO layer was
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quickly purified via extraction in isopropanol. Specifically, the Ln-SPIO material was
combined with 5 volumes of isopropanol and the mixture was vigorously shaken. Brief
centrifugation of the mixture resulted in a layer of precipitated salt, an Ln-SPIO layer,
and an isopropanol layer (containing any remaining epichlorohydrin). The SPIO layer
was then isolated and combined with an equal volume of concentrated NH4OH and
gently stirred for 24 hours at room temperature, resulting in an aminated nanoparticle
surface. After the reaction, the Ln-SPIO was purified by diafiltration across a 100 kDa
membrane and was 0.2 µm filtered to remove any oversized material. Finally, to ensure
complete purification of the Ln-SPIO from excess salt and lanthanide ions, the
nanoparticles were magnetically purified on MACS LS columns using a MidiMACS
magnet (Miltenyi Biotec, Auburn, CA, USA).
To prepare SPIO with different surface charges, aminated Ln-SPIO formulations
were reacted overnight with varying amounts of succinic anhydride (0 – 1 M) in 0.1 M
sodium bicarbonate buffer and subsequently purified by isopropanol precipitation.
Nanoparticles with distinct size distributions were obtained by differential centrifugation.
Specifically, iterative centrifugation at 10,000 RCF for 10 minutes, resulted in a final
nanoparticle pellet enriched for larger sizes. Smaller nanoparticles were obtained by
magnetic depletion (i.e. the flow-through of a MACS LS column was collected).
Necessarily, this resulted in SPIO without magnetic properties, but selected for smaller
nanoparticles, since particularly small iron cores do not have magnetic properties.

61

Nanoparticle Physicochemical Characterization
Ln-SPIO stock samples were diluted in deionized water and deposited on 200mesh carbon coated copper grids (Polysciences, Warrington, PA, USA) for TEM imaging
with a JEOL 1010 transmission electron microscope operating at 80 kV. Mean iron core
size was determined by measuring 100 individual nanoparticles. The presence of
lanthanide metal incorporated into SPIO nanoparticles, versus the background solution,
was assessed by energy dispersive X-ray spectroscopy (EDS) mapping using a JEOL
2010F. Stock samples of Ln-SPIO nanoparticles, dendrimers, polymersomes, and
liposomes were diluted into pH 7.4 phosphate buffered saline for determination of the
hydrodynamic diameter by dynamic light scattering (DLS). Measurements were acquired
with a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the noninvasive back-scatter (NIBS) mode. For zeta potential measurements, stock samples of
Ln-SPIO were diluted into either 10 mM HEPES buffered water at pH 7.4 or phosphate
buffered saline at pH 7.4 and then mean nanoparticle zeta potential was measured using a
Zetasizer Nano-ZS. For Ln-SPIO nanoparticles, the transverse (r2) and longitudinal (r1)
relaxivities were measured using a Bruker mq60 tabletop MR relaxometer operating at
1.41 T (60 MHz).

Nanoparticle Stability Assays
The stability of the nanoparticles was measured as the amount of lanthanide
leakage that could be observed in serum. Nanoparticles were incubated in 100% fetal
bovine serum (FBS) at 37°C with shaking. Aliquots were removed at 1, 2, 4, 6, and 24
hours and applied to a 4,000 MWCO centrifugal filter device to collect any free metal in
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the filtrate. Lanthanide concentrations were measured by ICP-MS in the original
nanoparticle stock and in the filtrates, allowing for calculation of percent of lanthanide
leakage.

Cell Culture and Tumor Model
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided
by Mark Greene, PhD, FRCP, University of Pennsylvania) were cultured and maintained
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin at 37°C and 5% CO2. Approximately 6-week
old female nu/nu nude mice (Charles River Laboratory, Charles River, MA, USA) were
maintained in accordance with the Institutional Animal Care and Use Committee of the
University of Pennsylvania. Mice were anesthetized via isoflurane and T6-17 cells were
injected subcutaneously into the back right flank (2 x 106 cells in 0.2 mL PBS). Tumors
were grown until the longest dimension was approximately 8 mm.

Quantitation of Tumor Delivery, Biodistribution, and Blood Concentration by ICP-MS
Three animal cohorts, each containing 3 animals, were used for multiplex
experiments, as outlined in Table 2.1. Each nanoparticle formulation was injected at a
dose of 10 mg Fe / kg body weight (for a total iron load of 30 mg/kg in each mouse) in
200 µL of injected solution.
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Table 2.1 Summary of animal injection groups (n=3 for all groups).
Experimental
Cohort
Negative Zeta
Potential
Positive Zeta
Potential
Size

Number of
Particles Coinjected
3
3
3

Description

-20.8 mV, -12.2 mV, -5.2 mV SPIO (all ≈ 28
nm)
+3.6 mV, +10.0 mV, +14.3 mV SPIO (all ≈ 28
nm)
15.52 nm, 29.05 nm, 70.72 nm SPIO (all ≈ -20
mV)

For each experimental group, prior to injection, a nanoparticle aliquot was saved
for inductively coupled plasma mass spectrometry (ICP-MS) determination of lanthanide
concentration in the injected material. Following nanoparticle injection, 10 µL blood
samples were collected from each animal, using the tail-nick method, at times of 1, 2, 4,
7, and 24 hours post-injection. After the final blood draw, the animals were sacrificed and
the tumors, livers, spleens, kidneys, hearts, and lungs excised.
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain,
NY, USA) and trace metal grade nitric acid and aqua regia was purchased from Fisher
Scientific (Pittsburg, PA, USA). All dilutions were done using in-house deionized water
(≥18 MΩ-cm) obtained from a Millipore water purification system.
The pre-injection solutions, blood, tumor, and organ samples were analyzed for
158

Gd (gadolinium),

147

Sm (samarium), 153Eu (europium), and 165Ho (holmium), using an

Elan 6100 ICP-MS (Perkin Elmer, Shelton, CT, USA)

at the New Bolton Center

Toxicology Laboratory, University of Pennsylvania, School of Veterinary Medicine,
Kennett Square, PA, USA. The samples were weighed into Teflon PFA vials (Savillex,
Minnetonka, MN, USA) and digested overnight with 70% nitric acid at 70° C. 0.1 mL of
2 ppm
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Tb (terbium) was added to each of the digested samples and the mixtures were
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diluted with deionized water to a final volume of 10 mL. The lanthanide concentration of
each sample was measured using a calibration curve of aqueous standards at 0.01, 0.1,
1.0, and 10 ppb for each metal.
The performance of the instrument and accuracy of the results were monitored by
analyzing a reagent blank and bovine serum control serum (Sigma) prior to analysis of
the samples. Also, standard reference material (Peach Leaves 1547) obtained from
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with
known values of iron and rare earth elements was analyzed with each batch of samples.
For each nanoparticle formulation, the percent injected dose per gram of tissue,
was calculated as [Ln]sample / ([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration
in the sample (blood, tumor, or organ tissue), [Ln]inj is the lanthanide concentration in the
injected nanoparticle solution, and Minj is the mass of nanoparticle solution injected (0.2
grams).

2.4 Results and Discussion
Synthesis of and Characterization of Ln-SPIO

Lanthanide doped superparamagnetic iron oxide (SPIO) nanoparticles were
prepared by including a small amount of lanthanide metal with the ferric and ferrous salts
during synthesis. Five different lanthanide metals (Gd, Eu, Ho, Sm, and Er) were
successfully incorporated into SPIO nanoparticles. Following synthesis and purification
of each Ln-SPIO formulation, differential centrifugation and chemical surface
modification were used to generate orthogonal sets of nanoparticles having either fixed
size and varying surface charge or fixed surface charge and varying size (Table 2.2).
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Table 2.2 Physicochemical properties of the nine unique Ln-SPIO formulations .
Tracer
Metal

Hydrodynamic
Diameter (nm)

Ho
Eu
Gd
Sm
Eu
Gd
Sm
Gd
Eu

15.52
29.05
70.72
29.84
28.61
26.06
29.16
27.29
29.47

Zeta Potential
(mV), HEPES, pH
7.4
-19.6
-20.7
-19.6
-20.8
-12.2
-5.2
+3.6
+10.0
+14.3

r2
-1 -1
(mM s )

r1
-1 -1
(mM s )

Core Size
(nm)

Ln /
Fe%

<5
141.75
214.97
150.41
137.18
123.66
142.38
106.76
176.58

< 0.5
9.35
2.26
9.99
9.10
11.79
9.22
10.31
8.87

5.1 ± 1.9
17.4 ± 3.0
41.1 ± 10.6
19.4 ± 3.9
19.2 ± 3.5
15.9 ± 2.7
19.8 ± 3.8
15.1 ± 2.6
18.6 ± 3.8

17.8
1.6
8.0
1.7
2.9
2.0
1.7
2.0
2.9

Specifically, to investigate the effect of surface charge, 6 nanoparticle
formulations were generated, each with a hydrodynamic diameter of approximately 28
nm but with zeta potentials ranging from -20.8 mV to +14.3 mV (Figure 2.2 A). Since it
was hypothesized that negatively and positively charged nanoparticles could not be
combined in a single injection due to electrostatic aggregation, these nanoparticles were
divided into two sets, one with three negatively charged nanoparticles and one with 3
positively charged nanoparticles. Consequently, only three different Ln-SPIO cores were
necessary (Gd, Eu, and Sm) for each of these studies. To investigate the effect of size,
three nanoparticle formulations were generated, each with a zeta potential of
approximately -20 mV, but with sizes of 15.52 nm, 29.05 nm, and 70.72 nm (Figure 2.2
B).
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Figure 2.2 Dynamic light scattering (DLS) size distributions for Ln-SPIO nanoparticles. (A) The six
nanoparticle formulations used to investigate the effect of zeta potential on nanoparticle biodistribution and
blood clearance have near-equivalent size distributions. (B) The three nanoparticle formulations that were
used to isolate the effect of size on nanoparticle biodistribution and blood clearance have distinct size
distributions (each with zeta potential ≈ -20 mV).

The mean core size for each formulation of Ln-SPIO was determined by
transmission electron microscopy (Table 2.2) and the core morphology was examined
(Figure 2.3 A-D). Consistent with SPIO previously synthesized by co-precipitation,8 the
medium and large size formulations have cores consisting of multiple individual crystals,
resulting in a heterogeneous appearance.
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Figure 2.3 TEM images of Ln-SPIO: Representative TEM images of (A) Sm-SPIO (core size, CS =
19.4±3.9nm, hydrodynamic diameter, HD = 29.84nm), (B) Eu-SPIO (CS = 19.2±3.5nm, HD = 28.61nm),
(C) Gd-SPIO (CS = 15.9±2.7nm, HD = 26.06nm) and (D) Ho-SPIO (CS = 5.1±1.9nm, HD = 15.52nm). All
scale bars are 100 nm.

Energy dispersive X-Ray spectroscopy (EDS) was used to further confirm that
each lanthanide metal was incorporated into the iron core. Specifically, when examining
the nanoparticles under transmission electron microscopy, EDS regions of interest placed
in the background (i.e. not containing any nanoparticles) yielded signatures of ions of the
buffer (Na, Cl) and the TEM grid itself (Cu), but no lanthanide was detectable in the
background solution. When the EDS region of interest was moved onto a group of
nanoparticles, very large Fe signatures were detected, as well as signatures corresponding
to the specific lanthanide that was used for that synthesis (Figure 2.4). EDS examination
of conventional SPIO nanoparticles yielded only iron signatures without any lanthanide
peaks.
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Figure 2.4 EDS spectra of background (Grid), iron only SPIO (Fe), and Ln-SPIO doped with either Eu,
Sm, Ho, or Gd, demonstrating specific incorporation of each lanthanide metal into the nanoparticle core.

MR imaging following a multiplex injection of SPIO nanoparticles provides little
information, since the contribution of each individual nanoparticle formulation cannot be
de-convoluted. Nevertheless, with the exception of Ho-SPIO, it was found that each LnSPIO nanoparticle used in the studies possessed magnetic relaxivities that were
comparable to un-doped dextran SPIO (Table 2.2). The Ho-SPIO used in the size study
had negligible magnetic relaxivity due to the method in which it was processed to obtain
the small size. Prior to processing, the Ho-SPIO had relaxivities similar to the other LnSPIO formulations.
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To ensure that the lanthanide metals within the core of each SPIO formulation
would not readily leach/leak from the nanoparticle following intravenous injection, the
stability of each Ln-SPIO was evaluated in serum (Figure 2.5). Upon exposure to 100%
serum for 24 hours at 37°C, each Ln-SPIO nanoparticle experienced less than 0.5%
leakage of lanthanide metal into the bulk solution. In fact, for two of the Ln-SPIO (Sm
and Eu) the amount of leakage was below the limit of detection (≈ 0.2%).

Figure 2.5 Stability of various lanthanide doped nanoparticles, assayed by percent of lanthanide leakage
observed after 24 hours of incubation in 100% serum at 37°C.

Effect of Surface Charge on SPIO Biodistribution
The surface charge of the nanoparticle (with a fixed hydrodynamic diameter of
approximately 28 nm) was found to have a significant impact on passive tumor delivery
(Figure 2.6). Specifically, the mildly negative SPIO formulation (-12.2 mV in 10 mM
HEPES) was found to have the highest tumor delivery at 2.05 % injected dose / gram
tumor 24 hours post-injection. Zeta potentials closer to neutrality (-5.2 mV and +3.6 mV)
had somewhat lower tumor delivery of 1.37 and 1.23 % ID/g, while more extreme
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negative values (-20.8 mV) resulted in even less tumor delivery (1.09 % ID/g). The
moderate and extreme positive values of zeta potential, at +10.0 mV and +14.3 mV,
resulted in the poorest tumor delivery (0.84 and 0.29 % ID/g, respectively).

Figure 2.6 Effect of SPIO surface charge on passive nanoparticle delivery to T6-1 flank tumors, 24 hours
post-injection (reported as percent injected dose per gram tumor tissue).

Nanoparticle accumulation in other organs (liver, spleen, kidney, lungs, and heart)
was also examined 24 hours post-injection (Figure 2.7). Large uptake was observed in
organs of the reticuloendothelial system (RES), with liver concentrations ranging from
25-45 % ID/g and spleen concentrations ranging from 13-40 % ID/g. The lungs, kidney,
and heart all showed modest uptake in the range of 0.5-2 % ID/g, with the notable
exception of the heart delivery of the three positively charged SPIO nanoparticles. It was
found that each positively charged SPIO had significantly elevated delivery to the heart,
in the range of 5-7 % ID/g. These data were confirmed with a second set of mice. It was
also found that at 5 minutes post-injection, the concentration of +14.3 mV SPIO
nanoparticles in a washed heart specimen was 12.2 % ID/g, while its concentration in the
blood at 5 minutes was only 2.3 % ID/g.
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Figure 2.7 Effect of SPIO surface charge on biodistribution, at 24 hours post-injection.
Finally, the blood clearance profile for each surface charge was investigated
(Figure 2.8). Similar to the results observed for tumor delivery, the -12.2 mV SPIO
demonstrated the longest blood circulation time, while the more neutral formulations (5.2 mV and +3.6 mV) had a shorter circulation time. The more positively charged
particles exhibited very rapid clearance, with the +14.3 mV formulation’s blood
concentration falling to 1.1 % ID/g in the first hour post-injection.

Figure 2.8 Effect of SPIO surface charge on blood clearance.
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It should be noted that the absolute value of a zeta potential measurement is
highly dependent on the identity and ionic strength of the buffer in which it is measured.
The zeta potentials (as measured in pH 7.4, 10 mM HEPES, with no additional salt) of
the 6 nanoparticle formulations tested in this investigation were -20.8, -12.2, -5.2, +3.6,
+10.0, and +14.3 mV. A low ionic strength buffer was selected to measure zeta potential
for this study in order to highlight relatively small differences in surface charge. In this
buffer, the -5.2 mV and +3.6 mV formulations should be considered close to neutral; the 12.2 mV and +10.0 mV are mildly negative and positive, respectively; the remaining two
formulations have more significant negative and positive charges.
Previous studies have demonstrated that prolonged blood circulation, and
therefore, optimal tumor delivery by the enhanced permeability and retention (EPR)
effect is achieved with nanoparticles displaying a neutral to mildly negative surface
charge.9,

10

When the surface charges becomes overly negative, excessive association

with phagocytic cells of the reticuloendothelial system (RES) decreases circulation time9,
10

and it has been commonly reported that positively charged nanoparticles are cleared

very rapidly due to local electrostatic interactions near the injection site.11
The results obtained in the two zeta potential experimental cohorts are consistent
with this general literature consensus, and the tumor delivery was found to correlate well
with blood circulation time, consistent with passive delivery by EPR. Specifically, the
mildly negative surface charge of -12.2 mV yielded the longest circulation time and
greatest tumor delivery. More neutral formulations resulted in slightly lower, but still
significant, circulation time and tumor delivery. Excessively negative SPIO (-20.7 mV)
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displayed still more rapid clearance and decreased tumor delivery, while moderately and
strongly positive formulations had poor circulation time and tumor delivery.
As expected, a large amount of the injected material, for all surface charges, was
found in the liver and spleen. However, the two surface charges that yielded the greatest
tumor delivery (-5.2 mV and -12.2 mV) exhibited the least liver uptake. The more
significantly negative formulation (-20.7 mV) had a larger liver uptake, consistent with
stronger association with Kupffer cells and clearance by the liver. Given its relatively
large mass, the liver represents a major mechanism by which nanoparticles are removed
from circulation, and since nanoparticles removed from circulation by the liver cannot
end up delivered to the tumor, it was reasonable to observe the liver concentration as
roughly inversely related to tumor delivery.
The relatively high concentration (≈ 6% ID/g) of positively charged nanoparticles
observed in the heart 24 hours post-injection was an unexpected finding that is likely due
to a “first pass effect”, since the right chambers of the heart are the first organ that the
nanoparticles reach after intravenous injection. In fact, washed heart tissue sampled at 5
minutes post-injection contained 12.2% ID/g. Since the nanoparticle concentration in the
blood at 5 minutes post-injection was only 2.3% ID/g, the high concentration of
nanoparticles detected in the heart cannot be attributed to residual blood in the chambers.
The results are consistent with a rapid initial interaction of the positively charged
nanoparticles with the endocardium, followed by approximately half of this initial load
being washed away during the next 24 hours.
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Effect of Nanoparticle Size on SPIO Biodistribution
The hydrodynamic diameter of SPIO nanoparticles (with a fixed zeta potential of
approximately -20 mV) was also found to influence their passive tumor delivery (Figure
2.9 A). Specifically, the smallest formulation of 15.52 nm yielded the greatest tumor
delivery at 1.61 % ID/g, the medium sized formulation of 29.05 nm resulted in a lower
delivery at 1.29 % ID/g, and the largest formulation of 70.72 nm demonstrated the lowest
delivery at 1.06 % ID/g. Similarly to the negatively charged SPIO tested in the previous
cohort of animals, all nanoparticle sizes demonstrated significant RES uptake (28 – 42 %
ID/g in the liver and 18 – 38 % ID/g in the spleen) and more modest uptake in the heart,
lungs, and kidneys (0.5 – 2 % ID/g, Figure 2.9 B).

Figure 2.9. Effect of SPIO hydrodynamic diameter on tumor delivery and biodistribution. (A) Passive
nanoparticle delivery to T6-17 flank tumors for three distinct SPIO size distributions. (B) Nanoparticle
uptake in other organs as a function of size.
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The blood clearance of the three different sizes tested proved especially
interesting (Figure 2.10). While the 29.05 nm, -20.7 mV nanoparticle exhibited a similar
circulation profile as it did in the previous cohort of animals, both the smaller
nanoparticle (15.52 nm) and the larger nanoparticle (70.72 nm) exhibited more prolonged
circulation.

Figure 2.10 Effect of SPIO hydrodynamic diameter on blood clearance.
Previous studies have shown that there is a window, roughly between 5 nm and
100 nm, in which nanoparticle blood circulation time and passive tumor delivery by EPR
is maximized.12-15 If the construct is too small, it can be rapidly and efficiently cleared
through the kidneys, but if too large (>200 nm), it is efficiently trapped by cells of RES
organs.16 All three SPIO sizes tested were comfortably above the renal filtration
threshold, so it was not surprising to observe an inverse relationship between nanoparticle
size and tumor delivery.
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However, unlike in the zeta potential studies, the tumor delivery was not observed
to be strictly correlated to circulation time (the largest SPIO, at 70.72 nm, demonstrated
the lowest tumor delivery, despite having intermediate circulation time). It is possible that
the 70.72 nm SPIO exhibit greater blood concentrations (especially at early time points)
because their larger size makes extravasation into tissue (including the tumor) more
difficult, but the size is not yet large enough to result in excessive interaction with cells of
the RES. It has also been demonstrated that diffusion-based penetration into tumors is
strongly dependent on nanoparticle size.17 It is likely the larger, 70.72 nm formulation,
was not able to efficiently diffuse through the tumor tissue and, therefore, experienced a
greater “wash out” effect over the 24 hours of the study.

2.5 Improved Statistical Power of Multiplex (Ratiometric) Data
One of the most promising aspects of this multiplex ICP-MS approach to
measuring biodistribution and blood clearance is the robust statistical power inherent in
injecting all nanoparticle formulations one wishes to compare into a single animal. In
vivo studies often exhibit a high degree of experimental variability (e.g. differences in
tumor size, subject weight, and physiology). When each nanoparticle formulation is
injected alone, comparison between formulations must be made with unpaired statistical
tests, which often necessitates a larger number of animals in order to detect statistically
significant differences in the performance of two or more nanoparticles. However, when
each nanoparticle is simultaneously administered to all animals, subject-to-subject
variability is effectively removed by the use of paired statistics. For example, the absolute
tumor delivery of two particular nanoparticle formulations might be highly variable
between three animals, confounding attempts to compare the formulations. However, if in
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each given subject, one nanoparticle is observed to have higher tumor delivery than the
other, one can more easily conclude that formulation is superior.
Looking at the statistical analysis of the experimental cohort (3 animals)
investigating the effect of nanoparticle size, between the 6 organs investigated for 3 sizes,
there were 18 head-to-head statistical comparisons that could be made. Treating the data
as unpaired, using P < 0.05 as the criterion, 6 of the comparisons were statistically
significant; treating the data as paired, 15 of the possible 18 comparisons demonstrated
statistical significance. To highlight a particular data set, the average kidney delivery of
the 15.52 nm, 29.05 nm, and 70.72 nm sizes were 1.74, 1.29, and 1.16 % ID/g,
respectively, each with a standard deviation of 0.26 – 0.29 % ID/g. These small
differences in nanoparticle concentration could not be deemed statistically different (P
values ranging from 0.06 to 0.59) from one another if the data are treated as unpaired.
However, given that in a given animal, the 15.52 nm nanoparticle always had the greatest
concentration, followed by 29.05 nm, and then 70.72 nm, paired statistics indicated that
each concentration was statistically different (P values ranging from 0.002 to 0.022).
However, it should not be assumed that paired statistics (compared to unpaired) always
necessarily result in a lower P value. In the experimental cohort investigating the effect of
nanoparticle surface charge, there were several instances in which unpaired statistics
would have produced P values less than 0.05 (which can always occur by chance when
such a large number of comparisons are made) but paired analysis resulted in a P value
greater than 0.05. The consequence of using paired statistics, therefore, is simply an
increase in statistic power (i.e. a more accurate estimation of whether the difference is
“real” can be obtained with a smaller sample size).
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2.6 Conclusion
A synthetic protocol to stably incorporate lanthanide metals into the core of SPIO
nanoparticles, without abolishing their magnetic properties, has been developed. The
lanthanide dopant can be used as a unique tracer atom, allowing the sensitive and
quantitative detection of the nanoparticles by ICP-MS, both in vitro and in vivo, without
interference from endogenous signals. When distinct lanthanide metals are incorporated
into nanoparticles with distinct physicochemical properties, ICP-MS allows for the
concentration of each nanoparticle formulation to be measured independently of other
formulations that may be present in the solution or tissue of interest. As a proof of
principle, this ICP-MS multiplex approach was used to evaluate the effect of nanoparticle
size and surface charge on tumor delivery, biodistribution, and blood clearance in vivo.
The results obtained were consistent with the general literature consensus about these
properties and only required a small number of experimental animals, due to the inherent
and robust statistical power of a multiplex (ratiometric) approach. Furthermore, it is
envisioned that the ICP-MS multiplex analysis described could prove to be a powerful
future research tool in the investigation of other nanoparticle formulations with diverse
physicochemical properties and active targeting capabilities, while allowing for
nanoparticle standardization.
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Chapter 3: Generalization of ICP-MS Analytical Method to Other
Nanoparticle Formulations and Validation of Multiplex Data
3.1 Abstract
The previous chapter outlined an analytical protocol for stably incorporating
lanthanide metals into the iron core of superparamagnetic iron oxide (SPIO)
nanoparticles and then using ICP-MS to quantify of the biodistribution and blood
clearance of multiple lanthanide-doped SPIO simultaneously administered to a single
animal. The method used for lanthanide incorporation (i.e. co-precipitation of iron and
lanthanide) was unique to SPIO. However, much greater utility can be gained if
lanthanide multiplex analysis could be applied to a wider range of nanoparticle
formulations. In this chapter, liposomes, polymersomes, dendrimers, and gold
nanoparticles were examined. With the exception of gold nanoparticles, incorporation of
the metal was accomplished using the chelator DTPA. In the case of the nanovesicles, the
lanthanide was chelated to DTPA and then encapsulated within the aqueous core. For the
dendrimers, DTPA was covalently conjugated to the nanoparticle surface. The gold
nanoparticles do not require an additional dopant, since the gold itself serves as an
orthogonal, non-endogenous tracer. Given that the most commonly used methods to
radiolabel

macropharmaceuticals

and

nanoparticles

exploit

radionuclide-chelate

complexes, the successful use of chelators to incorporate the tracer lanthanide
demonstrates that the ICP-MS multiplex approach can be conveniently substituted for
radiolabeling in biodistribution and clearance studies.
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3.2 Introduction
Given the variety and versatility of nanoparticle based carrier systems, it is not
surprising that there is tremendous research interest to develop nanoparticles into imaging
and therapeutic agents. Radionuclides play a major role in such studies since they provide
quantitative information and have very high sensitivity. For example, gamma emitters
such as

111

In and

99m

Tc or positron emitters such as

18

F and

64

Cu can be used as the

source of signal when designing nanoparticle based contrast agents for SPECT1-3 and
PET4-6 studies, respectively. For therapeutic studies of drug carrying nanoparticles, these
and other radionuclides such as

125

I can also serve as tracers, in order to determine the

level of payload delivery to the site of interest as well as assess off-target toxicity.
Furthermore, radionuclides such as

188

Re,(7,

8) 90

Y,(9)

131 (10)

I,

and

225

Ac(11,

12)

can

themselves provide the therapeutic effect (i.e. radiopharmaceutical nanoparticles).
Within the nanoparticle field, as well as the larger research community, there is a
great deal of experience working with radionuclides for imaging, tracing, and
radiotherapy. There are two very common ways to associate radionuclides with
nanoparticles. One is encapsulation, where a metal or non-metal radionuclide is noncovalently confined to the interior of the nanoparticle. For example, liposomes and
polymersomes possess and aqueous core capable of confining radionuclides13, 14 (as well
as many other materials including fluorophores and pharmaceuticals). The other common
approach is to covalently attach a chelator, such as DTPA or DOTA, to the nanoparticle
and then bind a metal radionuclide to the chelator.15, 16 Less commonly, nanoparticles are
formed using radiolabeled precursors.17
Radiolabeling is the “gold standard” for evaluating an agent’s pharmacokinetics
and biodistribution and the incorporation of metal radionuclides into nanoparticles and
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other macromolecules is well established practice. We sought to employ the same
common methods (i.e. encapsulation and chelation) to incorporate lanthanide tracers into
nanoparticles, thereby allowing for quantitative measurement of blood clearance and
tumor delivery using ICP-MS. However, unlike radiolabeling, an ICP-MS based
approach should allow for high level multiplexing of these measurements in single
animals. For further validation, we sought to confirm that the blood clearance profiles
and tumor delivery data obtained with the ICP-MS multiplex injection approach was both
reproducible across a range of injection pools and agreed with data obtained for
conventional single agent injection.

3.3 Materials and Methods
Synthesis of PAMAM (G3)−DOTA−Ho and PAMAM (G5)-DOTA-Pr

10 mg of PAMAM G3 dendrimer (ethylenediamine core, generation 3,
Dendritech, Midland, MI, USA) was dissolved in 4 mL of sodium bicarbonate buffer (0.1
M, pH 9.5) and reacted with 35 mg of DOTA-NHS-ester (Macrocyclics, Dallas, TX,
USA) for 10 hours. The pH of the solution was maintained at 9.5 over the course of the
reaction by addition of NaOH. The PAMAM−DOTA was purified by centrifugal filter
devices (Amicon Ultra-4, 5000 MWCO, Millipore, Billerica, MA). The purified
PAMAM−DOTA conjugates were mixed with 18 mg of HoCl3•6H2O in 0.1 M citrate
buffer (pH 5.6) overnight at 42°C. Finally, the dendrimer was purified from free Ho3+
with 5000 MWCO centrifugal filter devices. PAMAM (G5)-DOTA-Pr was prepared
using an analogous procedure, substituting PAMAM-G5 in the place of PAMAM-G3 and
PrCl3•6H2O for HoCl3•6H2O. In order to ensure the two dendrimer formulations were
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negatively charged, each was reacted overnight with 1 M succinic anhydride in 0.1 M
sodium bicarbonate buffer and then purified by centrifugal filtration.

Preparation of DOTA−Ce Encapsulating Polymersomes
DOTA-Ce was prepared by dissolving 303 mg of DOTA (Macrocyclics) in 3 mL
of citrate buffer (0.1 M, pH 5.6) and reacting with 223.8 mg of CeCl3•7H2O for 10 hours.
The reaction solution was maintained at pH 6.0 with NaOH. Polymersomes were
prepared by dissolving 20 mg of PEO-PBD block copolymer (polyethyleneoxide[600
Da]-block-polybutadiene[1200 Da], Polymer Source, Dorval, Quebec, Canada) in
chloroform in a glass vial and then evaporating the solvent using a stream of N2 gas.
After further drying under vacuum overnight, the residual polymer film was hydrated
with 1 mL DOTA-Ce aqueous solution in a 65 °C water bath for 30 min and then
sonicated for another 1 h at the same temperature. Polymersomes were subjected to ten
freeze–thaw–vortex cycles in liquid nitrogen and warm H2O (65 °C), followed by
extrusion 21 times through two stacked 100 nm Nuclepore polycarbonate filters using a
stainless steel extruder (Avanti Polar Lipids, Alabaster, AL). Unencapsulated DOTA-Ce
was removed via size-exclusion chromatography using Sepharose CL-4B (SigmaAldrich, St. Louis, MO, USA) and polymersomes were further purified through repeated
washing on centrifugal filter devices (Amicon Ultra-4, 100K MWCO, Millipore). Any
remaining positively-charged surface amino groups were then blocked by carboxylation
with succinic anhydride.
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Preparation of DOTA−Dy Encapsulating Liposomes
DOTA-Dy was prepared by dissolving 303 mg of DOTA in 3 mL of citrate buffer
(0.1 M, pH 5.6) and reacting with 226.2 mg of DyCl3•6H2O for 10 hours. The reaction
solution was maintained at pH 6.0 with NaOH. For liposome synthesis, hydrogenated soy
phosphatidylcholine

(HSPC),

cholesterol,

phosphoethanolamine-N-[methoxy-(polyethylene

and

1,2-distearoyl-sn-glycero-3-

glycol)-2000]

(mPEG2000-DSPE)

were obtained from Avanti Polar Lipids. 10 mg of 55 mol% HSPC/40 mol%
CHOL/5 mol% mPEG2000-DSPE mixture was dissolved in chloroform in a glass vial,
followed by evaporation of the solvent with a stream of N2 gas and further drying under
vacuum for at least 4 hours. DOTA-Dy encapsulating liposomes were then synthesized
and purified with a procedure analogous to the preparation of DOTA-Ce encapsulating
polymersomes.

Preparation of PEG-coated Gold Nanoparticles
Gold nanoparticles were prepared according to a protocol established by
Turkevich.18 Briefly, 200 ml of aqueous 0.01% (w/v) HAuC14 was brought to a boil and
then 7 ml of aqueous 1% (w/v) sodium citrate was added. The color of the solution
initially changed to a grayish-black and then to red within a few minutes. The solution
was allowed to cool at room temperature and then filtered through a 0.2 µm pore size
nylon filter system. The AuNPs were then coordinated with HS – PEG (5K) – OCH3
(Sigma Aldrich) at a mass ratio of 8:1 HS – PEG - OCH3:Au. After 2 hours of constant
stirring, the AuNP solution was then purified from excess reactants using 50K MWCO
centrifugal filter devices.
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Nanoparticle Physicochemical Characterization
Stock samples of dendrimers, polymersomes, liposomes, and gold nanoparticles
were diluted into pH 7.4 phosphate buffered saline for determination of the
hydrodynamic diameter by dynamic light scattering (DLS). Measurements were acquired
with a Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the noninvasive back-scatter (NIBS) mode. For zeta potential measurements, stock samples were
diluted into phosphate buffered saline at pH 7.4 and then mean nanoparticle zeta potential
was measured using a Zetasizer Nano-ZS.

Nanoparticle Stability Assays
The stability of the nanoparticles was measured as the amount of lanthanide
leakage that could be observed in serum. Nanoparticles were incubated in 100% fetal
bovine serum (FBS) at 37°C with shaking. Aliquots were removed at 1, 2, 4, 6, and 24
hours and applied to a 4,000 MWCO centrifugal filter device to collect any free metal in
the filtrate. Lanthanide concentrations were measured by ICP-MS in the original
nanoparticle stock and in the filtrates, allowing for calculation of percent of lanthanide
leakage.

Cell Culture and Tumor Model
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided
by Mark Greene, PhD, FRCP, University of Pennsylvania) were cultured and maintained
in Dulbecco’s modified Eagle’s medium (DMEM), supplemented with 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin at 37°C and 5% CO2. Approximately 6-week
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old female nu/nu nude mice (Charles River Laboratory, Charles River, MA, USA) were
maintained in accordance with the Institutional Animal Care and Use Committee of the
University of Pennsylvania. Mice were anesthetized via isoflurane and T6-17 cells were
injected subcutaneously into the back right flank (2 x 106 cells in 0.2 mL PBS). Tumors
were grown until the longest dimension was approximately 8 mm.

Quantitation of Tumor Delivery, Biodistribution, and Blood Concentration by ICP-MS
Two animal cohorts, each containing 3 animals, were used for multiplex
experiments, as outlined in Table 3.1. In the first experimental groups, which investigated
a single type of SPIO, the nanoparticles were injected at a dose of 10 mg Fe / kg body
weight in 200 µL of injected volume. In the second experimental group, which included a
variety of additional nanoparticle platforms, the SPIO was injected at 10 mg Fe / kg body
weight and the other formulations were injected at concentrations so that all tracer metal
concentrations (lanthanide or gold) were approximately equal to that of the SPIO
samples, ≈ 34 ppm, in 200 µL of injected solution.

Table 3.1. Summary of animal injection groups (n=3 for each groups).
Experimental
Cohort
Single Particle
Additional
Platforms

Number of
Particles Coinjected
1
7

Description

-20.8 mV, 29.8 nm SPIO
Gd-DTPA, G3 and G5 dendrimers, AuNP, SPIO,
liposome, polymersome
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For each experimental group, prior to injection, a nanoparticle aliquot was saved
for inductively coupled plasma mass spectrometry (ICP-MS) determination of lanthanide
concentration in the injected material. Following nanoparticle injection, 10 µL blood
samples were collected from each animal, using the tail-nick method, at times of 1, 2, 4,
7, and 24 hours post-injection. After the final blood draw, the animals were sacrificed and
the tumors, livers, spleens, kidneys, hearts, and lungs excised.
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain,
NY, USA) and trace metal grade nitric acid and aqua regia was purchased from Fisher
Scientific (Pittsburg, PA, USA). All dilutions were done using in-house deionized water
(≥18 MΩ-cm) obtained from a Millipore water purification system.
The pre-injection solutions, blood, tumor, and organ samples were analyzed for
158

Gd (gadolinium),

(erbium),

161

147

Sm (samarium),

Dy (dysprosium),

140

153

Eu (europium),

Ce (cerium),

141

165

Ho (holmium),

Pr (praseodymium), and

197

166

Er

Au (gold)

using an Elan 6100 ICP-MS (Perkin Elmer, Shelton, CT, USA) at the New Bolton
Center Toxicology Laboratory, University of Pennsylvania, School of Veterinary
Medicine, Kennett Square, PA, USA. The samples were weighed into Teflon PFA vials
(Savillex, Minnetonka, MN, USA) and digested overnight with 70% nitric acid (or aqua
regia for gold containing samples) at 70° C. 0.1 mL of 2 ppm 159Tb (terbium) was added
to each of the digested samples and the mixtures were diluted with deionized water to a
final volume of 10 mL. The lanthanide (or gold) concentration of each sample was
measured using a calibration curve of aqueous standards at 0.01, 0.1, 1.0, and 10 ppb for
each metal.
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The performance of the instrument and accuracy of the results were monitored by
analyzing a reagent blank and bovine serum control serum (Sigma) prior to analysis of
the samples. Also, standard reference material (Peach Leaves 1547) obtained from
National Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with
known values of iron and rare earth elements was analyzed with each batch of samples.
For each nanoparticle formulation, the percent injected dose per gram of tissue,
was calculated as [Ln]sample / ([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration
in the sample (blood, tumor, or organ tissue), [Ln]inj is the lanthanide concentration in the
injected nanoparticle solution, and Minj is the mass of nanoparticle solution injected (0.2
grams).

3.4 Results and Discussion
Generalization of ICP-MS Multiplex Method with Additional Nanoparticle Platforms

In order to demonstrate the generalizability and versatility of the ICP-MS
multiplex approach, orthogonal metals were incorporated into a wide range of
nanoparticle platforms and their tumor delivery and blood clearance was examined.
Specifically, the small molecule Gd-DTPA, PAMAM dendrimers of generation 3 and 5,
PEG coated gold nanoparticles, SPIO, a polymersome, and a liposome were all
synthesized and conjugated to or encapsulated with orthogonal metals (Table 3.2).
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Table 3.2 Size and zeta potential of the nanoparticles used in the multiplatform study.
Particle

Tracer Metal

Gd-DTPA
G3 Dendrimer
G5 Dendrimer
Gold NP
SPIO
Polymersome
Liposome

Gd
Ho
Pr
Au
Er
Ce
Dy

Hydrodynamic
Diameter (nm)
-4.2
6.1
26.0
33.3
82.5
93.8

Zeta Potential (mV),
PBS, pH 7.4
--0.38
-7.58
-1.31
-9.55
-4.08
-1.35

The hydrodynamic diameter of these formulations was then measured in PBS,
along with their surface charge (zeta potential), using DLS and electrophoretic mobility.
Due to its very small size, the individual Gd-DTPA complex, however, is not amenable
to DLS measurement. These results are reported in Table 3.2. All nanoparticle
formulations possessed a neutral to moderately negative surface charge, making them
compatible for co-injection. This group of nanoparticles spanned a wide range of sizes,
from approximately 4 to 95 nm (Figure 3.1).

Figure 3.1. Size distributions of the nanoparticles (G3 and G5 dendrimer, gold (Au), SPIO,
polymersome, and liposome) used in the multiplatform study.
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The stability of the dendrimer chelates and nanovesicle formulations was also
confirmed by incubation in 100% serum for 24 hours at 37°C. It was found that less than
0.4% of the lanthanide metal was released from the dendrimer chelates into the bulk
solution, and less than 1.5% of the lanthanide metal encapsulated within the liposome and
polymersome was released into the bulk solution (Figure 3.2).

Figure 3.2 Stability of various lanthanide doped nanoparticles, assayed by percent of lanthanide leakage
observed after 24 hours of incubation in 100% serum at 37°C.

These 7 formulations were simultaneously injected and their tumor delivery
(Figure 3.3 A) and blood clearance (Figure 3.3 B) were evaluated. The small molecule
Gd-DTPA and smallest particle (G3 dendrimer, 4.2 nm) had tumor delivery at or below
the detection limit of 0.17% ID/g at 24 hours, and were entirely cleared from circulation
in the first hour post-injection. Interestingly, the G5 dendrimer, with a size only slightly
larger than the G3 dendrimer (6.1 nm) exhibited the greatest tumor delivery at 4.36%
ID/g and a prolonged circulation time, with 5.83% ID/g still circulating at 24 hours postinjection. The significantly larger PEG-coated gold nanoparticle also demonstrated very
robust tumor delivery at 4.00% ID/g and significantly lower clearance than any other
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formulation tested, with 15.20% ID/g remaining in circulation 24 hours post-injection.
The SPIO nanoparticle had tumor delivery and blood circulation times comparable to the
studies in the previous chapter. The polymersome and liposome yielded lower tumor
delivery (0.35% ID/g and 1.00% ID/g, respectively), and correspondingly, faster blood
clearance.

Figure 3.3 ICP-MS multiplex analysis of biodistribution and blood clearance for seven different
compounds injected simultaneously. (A) Tumor delivery and (B) blood clearance profiles for a variety of
lanthanide doped nanoparticle formulations, spanning a range of sizes, including small molecules,
dendrimers, gold nanoparticles, SPIO nanoparticles, polymersomes, and liposomes.

The small molecule Gd-DTPA and the G3 dendrimer both had undetectable tumor
delivery at 24 hours post-injection and had been cleared from circulation in the first hour
post-injection. This is consistent with previous reports of G3 dendrimer’s rapid
clearance.19 Since both of these formulations are less than 5 nm in diameter, they are
efficiently removed from circulation by renal filtration, and while they may display
dynamic wash-in at the tumor site, their small size allows for efficient wash-out and,
subsequently, poor tumor delivery at the 24 hour time point.
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It has been reported that G5 dendrimer exhibits a significantly longer circulation
time compared to G3,20 as the G5 dendrimer’s small increase in size begins to impair
renal filtration. In this study, the addition of the chelator DOTA, and surface modification
with succinate (to neutralize the positive charge of a native PAMAM dendrimer) also
contributes to increased size for the G5 formulation. The long circulation time observed
in this study, and consequent high tumor delivery, was likely due to the formulation being
too large for renal clearance, but still being small enough to avoid significant RES
interaction.
The PEG-coated gold nanoparticle also exhibited very long circulation time and
high tumor delivery. This was not unexpected since a PEG coating often confers “stealth”
properties to nanoparticles21 and many gold nanoparticle formulations have been reported
to have relatively long circulation times.22 The ≈ -20 mV, ≈ 30 nm SPIO demonstrated
similar clearance and tumor delivery as it did in the previous experimental cohorts.
Compared to the SPIO nanoparticles, the liposome and polymersome each displayed
more rapid clearance and, consequently, lower tumor delivery.

Validation of Multiplex Approach across Multiple Experimental Cohorts

A central assumption for all of the multiplex injection experiments is that the
different nanoparticle formulations do not interact with each other, so that tumor delivery,
biodistribution, and blood clearance observed in a multiplex injection are the same as
they would be if each formulation were injected separately. The experimental cohorts
used in this investigation, as well as the previous chapter, were specifically designed to
test and validate this assumption (see table 3.3). A specific form of SPIO nanoparticle (≈
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30 nm hydrodynamic diameter and ≈ -20 mV zeta potential, represented with bold text in
table 3.3) was present in the multiplex injection of 3 different animal cohorts (negative
zeta potential, size, and additional platforms), allowing for comparison of clearance and
tumor delivery for this nanoparticle across a range of injection conditions. It should be
noted that the zeta potential reported for the SPIO nanoparticle in Table 3.2 (-9.55 mV)
was measured in isotonic phosphate buffered saline; zeta potential measured in 10 mM
HEPES yielded ≈ -20 mV. Also, this formulation of SPIO was injected alone, in order to
explicitly compare tumor delivery and clearance to the values obtained in the different
multiplex injections.

Table 3.3 Summary of animal injection groups from this and previous chapter that all
contain a specific SPIO formulation (n=3 for all groups).
Experimental
Cohort
Single Particle
Negative Zeta
Potential
Size
Additional
Platforms

Number of
Particles Coinjected
1
3
3
7

Description

-20.8 mV, 29.8 nm SPIO
-20.8 mV, -12.2 mV, -5.2 mV SPIO (all ≈ 28
nm)
15.52 nm, 29.05 nm, 70.72 nm SPIO (all ≈ -20
mV)
Gd-DTPA, G3 and G5 dendrimers, AuNP,
33 nm, ≈ -20 mV SPIO, liposome, polymersome

The tumor delivery of this SPIO formulation conserved across animal cohorts is
summarized in Figure 3.4. For each injection condition tested, the tumor delivery was
very similar (1.09 – 1.29 % ID/g), and no two conditions were statistically different (P
values ranging from 0.33 to 0.85).
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Figure 3.4 Comparison of tumor delivery of a single SPIO nanoparticle formulation (≈ 29 nm, ≈ -20
mV) that was injected across multiple studies. No statistical difference is found between tumor delivery
obtained when the same SPIO formulation is injected alone, with SPIO of other charges, with SPIO of
other sizes, or with various other nanoparticle platforms.

Blood circulation profiles are compared in Figure 3.5; again, the four injection
conditions tested resulted in similar clearances, with overlapping error bars.

Figure 3.5 Validation of the ICP-MS multiplex method by comparing blood clearance of a single SPIO
nanoparticle formulation (≈ 29 nm, ≈ -20 mV) injected alone, with SPIO of other charges, with SPIO of
other sizes, or with various other nanoparticle platforms.
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As previously stated, in order for the ICP-MS multiplex method to provide
reliable data, it is important that the particular formulations that are co-injected together
do not exhibit interactions with each other, so that in the co-injection they behave as they
otherwise would if injected alone. In general, three potential sources of nanoparticle
interaction should be considered: hydrophobic interactions, electrostatic interactions, and
molecular specific interactions. For this particular investigation, all nanoparticle
formulations possessed a significantly hydrophilic surface, and no nanoparticles
possessed any specific ligands or receptors. In order to avoid electrostatic interactions,
when the effect of nanoparticle surface charge was evaluated, the study was split into two
separate injections (one with the three negatively charged particles, and one with the
three positively charged particles). It is also worth noting that at no time, for any of the
experimental groups, was any aggregation visibly observed when the individual
formulations were combined to form the multiplex solution. Given that each nanoparticle
would be “multivalent” for any possible type of interaction, macroscopic aggregation or
precipitation would be expected if nanoparticle interaction had occurred.
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3.5 Conclusion
In addition to precipitating lanthanide metals into the core of SPIO nanoparticles,
it is also possible to incorporate lanthanides into liposomes, polymersomes, and
dendrimeric formulations using either encapsulation or chelation. Therefore, it is
envisioned that any nanoparticle formulation amenable to labeling with a metal
radionuclide would also be suitable for labeling with an ICP-MS lanthanide tracer. Some
other types of nanoparticles (e.g. gold and silver nanoparticles) inherently contain an
ICP-MS metal tracer, without any further need for labeling. In addition to providing a
quantitative method of detection with high sensitivity, ICP-MS tracers provide two
potential befits over conventional radiolabeling. Namely, they have the ability to easily
multiplex a large number of signals in a single fluid or tissue sample while avoiding the
hazards of handling radioactivity. Consequently, ICP-MS based multiplex analysis can be
applied to a very wide variety of nanoparticle and macropharmaceutical formulations and
allows for “higher throughput” evaluation of the pharmacokinetics and biodistribution of
such agents in animals models.
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Chapter 4: Extension of ICP-MS Multiplex Method to Compare
Actively Targeted SPIO Nanoparticles
4.1 Abstract
Given the rapidly expanding library of pathology biomarkers (e.g. tumor
receptors) and targeting scaffolds (e.g. antibodies, single chain antibody fragments, small
affinity peptides, etc.), the number of actively targeted nanoparticle formulations is
growing exponentially. In most studies, the goal is to maximize the concentration of
diagnostic or therapeutic nanoparticle payload delivered to a site of interest in vivo, while
minimizing delivery in other locations. Given the difficulty and expense of in vivo animal
testing, it is generally not feasible to examine a large number of specific nanoparticle
candidates in vivo. This often leads to the investigation of only the single formulation that
performed best in vitro. However, nanoparticle delivery in vivo is dependent on many
variables, many of which cannot be adequately assessed with in vitro cell-based assays.
Consequently, the development of actively targeted nanoparticles could be greatly
facilitated and expedited by a method that allows for many formulations (including
control formulations) to be evaluated in a single animal. It is hypothesized that the ICPMS multiplex approach developed in chapters 2 and 3 to examine passive nanoparticle
delivery could be naturally extended to fill this role.
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4.2 Introduction
Rapid advancements in nanotechnology have resulted in the development of
nanoparticle formulations for a myriad of biological applications extending from
diagnostic cell tracking to improved delivery of therapeutic agents. Given the limitless
ability to modify the physicochemical properties of nanoparticles to fit specific areas of
interest, it is expected that their utility will only continue to increase. Recently, there has
been especially significant growth in the application of nanoparticles to cancer
diagnostics and drug delivery. This growth is a direct result of the numerous advantages
that nanoparticles provide to this field; including, but not limited to: the ability of
nanoparticles to extravasate at a tumor, the high therapeutic and diagnostic “payloads”
that can be incorporated into nanoparticles, and their favorable toxicity profiles resulting
from reduced agent accumulation in healthy tissue.1-3
So far, the majority of clinical trials for nanoparticles have focused on passive
delivery to the tumor. That is, a nanoparticle’s physicochemical properties are optimized
for long blood residence time, which allows for a high percentage of uptake into tumors
via the enhanced permeability and retention (EPR) effect.4 While this strategy has
demonstrated that nanoparticle-encapsulated drug has improved efficacy and reduced
side-effects (compared to free drug), an increased focus has recently been placed on
further improving these nanoparticles with active targeting strategies. Indeed, many
studies have shown that active targeting of nanoparticles can increase the dose of
therapeutic delivered to a tumor and also improve the intra-tumoral localization of
delivered nanoparticles.5,

6

Furthermore, a nanoparticle’s surface may display multiple

copies of a particular targeting ligand (multivalency), and this has been shown to increase
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binding avidity, increase the rate of internalization, and ultimately improve therapeutic
efficacy and/or image contrast.7-11
One particular class of nanoparticles that has become increasingly dependent on
targeted delivery is superparamagnetic iron oxide (SPIO) nanoparticles (NPs). SPIO NPs
are an attractive magnetic resonance (MR) contrast agent, providing T2*-weighted
contrast enhancement in MR imaging applications. Due to their good biocompatibility,
strong contrast enhancement, and their ability to generate functional data concomitant
with anatomic information, SPIO are avidly being evaluated as molecular imaging
agents. In this role, they are used to report the expression level of target cell-surface
receptors in order to improve the specificity of disease detection. To date, affinity
ligands have been used to deliver SPIO NPs to a range of different sites including tumor
cells,12,13 tumor vasculature,14,15 atherosclerotic lesions,16-18 and many others.19-24
However, while SPIO NPs have seen extensive biological applications, their full
transition to the clinic as molecular imaging agents has been slow to develop, due to the
relatively high concentrations of SPIO NPs needed to generate detectable MR contrast in
an area of interest.
Often, pathologies present with several possible biomarkers that may be viable
targets. For example, breast cancers may overexpress the estrogen receptor, progesterone
receptor, and/or the Her2/neu (ErbB2) receptor.25 As nanoparticles continue to progress
toward greater clinical use, it is important to identify which molecular targets result in the
best in vivo tumor delivery (for a particular tumor type). Importantly, the optimal
molecular target and nanoparticle composition for nanoparticle delivery in vivo may not
be accurately reflected in assays conducted in vitro. For example, it has been shown that
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affinity ligands with very high affinity do not necessarily result in the best tumor
targeting, since tight binding at the tumor periphery slows diffusion of the agent within
the tumor and can block extravasation of additional agent.26 Furthermore, the addition of
targeting ligands to a nanoparticle’s surface can alter its physicochemical properties, thus
potentially altering its circulation properties and affecting its ability to reach a tumor.
Despite the large potential for incongruity between nanoparticle performance in vitro
and in vivo, most often investigators choose the identity of the active targeting ligand and
then optimize the ligand surface density, along with other nanoparticle physicochemical
properties, based on in vitro data. Subsequently, this “optimal” formulation is generally
evaluated in one cohort of subjects, while one or more negative control (non-targeted)
nanoparticle formulations are examined in other cohorts. However, when nanoparticles
are evaluated in separate animal cohorts, the large animal-to-animal variability
characteristic of in vivo studies makes nanoparticle improvement more difficult to
observe. The primary reason for the lack of optimization at the in vivo stage, and the use
of a large number of animals, is the lack of a feasible “higher throughput” method for
accurately comparing different nanoparticles in vivo. In chapters two and three, we
introduced a non-radiative, quantitative, and multiplex method for assessing nanoparticle
pharmacokinetics and biodistribution, demonstrating its ability to compare passive
delivery for a wide range of nanoparticle types and physicochemical properties. Herein,
this method is extended to include the evaluation of actively targeted SPIO NPs.
For this work, we have selected three targets of interest: the HER2/neu receptor, heat
shock protein 47 (HSP47) and αVβ3 integrin. Each of these receptors has been shown to
have a high association with cancer, and each has been used as a target in therapeutic
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studies.27-30 Additionally, each of these targets has ligands that can be used to actively
target SPIO NPs. Specifically, HER2 affibody, cyclic RGD, and the LDS affinity peptide
were selected as ligands for targeting HER2/neu, αvβ3 integrin, and HSP47
respectively.31-36 As described in chapter 2, a set of four lanthanide-doped SPIO
nanoparticles (Ho, Sm, Gd, and Eu) were synthesized. HER2 affibody, cyclic RGD, and
LDS peptide were conjugated to the Ho-, Sm-, and Gd-SPIO, respectively. The Eu-SPIO
lacked a targeting ligand and served as a negative control nanoparticle formulation. ICPMS multiplex analysis can then be used to trace each actively targeted formulation
simultaneously in a single sample.

4.3 Materials and Methods
Materials

Azido-dPEG4-NHS ester was purchased from Quanta BioDesign Ltd. (Powell,
OH). NIH/3T3 cells that were engineered to stably express the Her2/neu receptor (T6-17)
were kindly provided by Dr. Mark Greene, MD/PhD (University of Pennsylvania). All
other reagents were purchased from Thermo Fisher Scientific (Waltham, MA) unless
otherwise noted.

Synthesis of Dextran Stabilized Lanthanide Doped SPIO

Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran

37

.

Briefly, 25 g of dextran T-10 (Pharmacosmos A/S, Holbaek, Denmark), was dissolved in
500 mL dH2O and heated to 80°C for 1 hour. The solution was then allowed to cool to
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room temperature and continued to mix overnight. Subsequently, a solution of 1.85 g
FeCl3, 0.73 g FeCl2, and 0.125 g LnCl3•6H2O (Ln = Ho, Eu, Sm, or Gd) in 25 mL dH2O
was prepared and decanted into the dextran solution. The combined solution was cooled
on ice and degassed with N2 for 90 min. While keeping the solution stirring on ice and
under N2, an automated syringe pump was then used to introduce 15 mL of concentrated
NH4OH to the solution over 5 hours. The resulting black viscous solution was removed
from the N2 atmosphere, heated to 90°C for 1 hour, cooled overnight, and centrifuged at
20,000 RCF for 30 minutes to remove large aggregates. Free iron, lanthanide, and
dextran were removed by diafilitration across a 100 kDa membrane and the Ln-SPIO
were brought to a final volume of ≈40 mL at 10 mg Fe/mL.
This 40 mL of dextran SPIO at an iron concentration of 10 mg/mL was then
combined with an equal volume of 10 M NaOH and mixed for 10 minutes. 80 mL of
epichlorohydrin was then added and the solution was vigorously stirred at room
temperature overnight. Epichlorohydrin crosslinks the dextran coating within the LnSPIO particle and chemically activates the dextran surface for conjugation. The solution
was then briefly centrifuged to allow phase-separation into an aqueous black SPIO layer
and a clear layer of unreacted epichlorohydrin, which was removed. The SPIO layer was
quickly purified via extraction in isopropanol. Specifically, the Ln-SPIO material was
combined with 5 volumes of isopropanol and the mixture was vigorously shaken. Brief
centrifugation of the mixture resulted in a layer of precipitated salt, an Ln-SPIO layer,
and an isopropanol layer (containing any remaining epichlorohydrin). The SPIO layer
was then isolated and combined with an equal volume of concentrated NH4OH and
gently stirred for 24 hours at room temperature, resulting in an aminated nanoparticle
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surface. After the reaction, the Ln-SPIO was purified by diafiltration across a 100 kDa
membrane and was 0.2 µm filtered to remove any oversized material. Finally, to ensure
complete purification of the Ln-SPIO from excess salt and lanthanide ions, the
nanoparticles were magnetically purified on MACS LS columns using a MidiMACS
magnet (Miltenyi Biotec, Auburn, CA, USA).

Cloning of HER2-Affibody and LDS Recombinant Protein into pTXB1 Vector
The nucleotide and corresponding amino acid sequences for the HER2 affibody
and LDS affinity peptide are provided in Figures 4.1 and 4.2, respectively.
Complementary oligonucleotides comprising the HER2-Affibody or LDS coding
sequence flanked at both ends by 15 base sequences homologous to the desired restriction
sites of the destination vector were ordered from Integrated DNA Technologies
(Coralville, IA). To improve subsequent affinity column cleavage, an additional 9 base
pairs encoding a “MRM” amino acid sequence were included in the oligonucleotides at
the C-terminal end of both sequences. The full nucleotide and amino acid sequence for
the HER2-Affibody and AHNP can be found in Figure x. Oligonucleotides were
incubated together at a final concentration of 5 µM and hybridized at room temperature
for 30 minutes. The resulting sequence was agarose gel purified and directly ligated with
gel-purified NdeI-XhoI double digested pTXB1 vector (New England Biolabs, Inc) via
the CloneEZ kit (Genscript). Insertion of the HER2-Affibody and AHNP sequences was
verified by DNA sequencing using the T7 promoter as the sequencing primer.
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GTG GAT AAC AAA TTT AAC AAA GAA ATG CGC AAC GCG TAT TGG GAA ATT
Val Asp Asn Lys Phe Asn Lys Glu Met Arg Asn Ala Tyr Trp Glu Ile
GCG CTG CTG CCG AAC CTG AAC AAC CAG CAG AAA CGC GCG TTT ATT CGC
Ala Leu Leu Pro Asn Leu Asn Asn Gln Gln Lys Arg Ala Phe Ile Arg
AGC CTG TAT GAT GAT CCG AGC CAG AGC GCG AAC CTG CTG GCG GAA GCG
Ser Leu Tyr Asp Asp Pro Ser Gln Ser Ala Asn Leu Leu Ala Glu Ala
AAA AAA CTG AAC GAT GCG CAG GCG CCG AAA ATG CGC ATG
Lys Lys Leu Asn Asp Ala Gln Ala Pro Lys Met Arg Met

Figure 4.1 Nucleotide and corresponding amino acid sequence of the HER2-Affibody.
The additional base pairs added to improve affinity column cleavage are shown in bold.

CTG GAT AGC CGC TAT AGC CTG CAG GCG GCG ATG TAT ATG GCG ATG
Leu Asp Ser Arg Tyr Ser Leu Gln Ala Ala Met Tyr Met Arg Met

Figure 4.2 Nucleotide and corresponding amino acid sequence of the LDS peptide. The
additional base pairs added to improve affinity column cleavage are shown in bold.
Expression and Purification of HER2-Affibody and LDS Recombinant Protein

The pTXB1-HER2-Affibody vector was transformed in Rosetta™ 2(DE3)pLysS
Competent Cells (Novagen). Bacterial cell cultures were initially grown overnight in an
air shaker (225 rpm) at 37 °C in 3 mL of LB medium. Cultures were scaled up to fifty
mL of LB medium and grown overnight under the same conditions, and then inoculated
into 1 L LB containing 50 mg/L of ampicillin. At OD600 nm = 0.6, IPTG was added at a
final concentration of 0.5 mM to induce T7 RNA polymerase-based expression. Cultures
were allowed to express for 2 hours at 37 °C. Bacterial cultures were centrifugally
pelleted at 10,000 x g for 5 minutes, resuspended in 5 mL of column buffer (20 mM Na110

HEPES, 0.5 M NaCl, 1 mM EDTA, pH 8.5) containing 0.75 g/L lysozyme and 50 mM
phenylmethylsulfonyl fluoride. Cells were lysed by pulse sonication on ice. Cells were
centrifuged at 15,000 g for 30 minutes at 4 °C. Supernatant was collected and stored at 20 °C. For the following purification steps, all procedures were run at 4 °C. One mL of
the supernatant was incubated for 10 minutes in a 10 mL Poly-Prep chromatography
column (Bio-Rad, Hercules, CA) packed with 1 mL of chitin beads (New England
Biolabs, Inc). Supernatant was allowed to pass through the column and chitin beads were
washed with 50 mL of column buffer at a flow rate of approximately 2 mL/min. Three
mL of 50 mM MESNA was quickly passed through the column in order to evenly
distribute the MESNA throughout the chitin beads, and flow was stopped. The column
was incubated for 16 hours at 4 °C. HER2-Affibody proteins, now containing a Cterminal thioester, were eluted from the column in a total 4 mL buffer (0.1 M Tris-HCl,
pH 8.5) and concentrated to a volume of 500 µL using an Ultracell 3,000 (Millipore,
Billerica, MA). An analogous experimental protocol was used for the production and
purification of LDS peptides, with the exception of the IPTG concentrations used for
induction, which were lowered from 0.5 mM to 0.4 mM final concentration.
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Figure 4.3 Schematic of EPL-Click conjugation strategy, illustrated with HER2 affibody
conjugation to Ho-SPIO. Upon cleavage from the chitin affinity purification column, the
HER2 affibody displays a C-terminal reactive thioester. This C-terminal thioester reacts
with the N-terminal cysteine of a fluorescent linker peptide (AFP). Towards the Cterminus of the linker peptide is an azide group. Subsequently a chemoselective “click”
reaction is carried out between Ho-SPIO displaying alkyne functional groups (ADIBO)
and the azide group of the HER2-linker adduct.

Expressed Protein Ligation
Expressed protein ligation was carried about between the thioester containing
HER2-Affibody/LDS peptide and an azido-fluorescent peptide (AzFP) with an Nterminal cysteine. The sequence of the AzFP was NH2-CDPEK(5-FAM)DSGK(N3)SOH. The K(5-FAM) represents a lysine with a fluorescein covalently attached to its εamino group and the K(N3) represents a lysine with an azido group attached to its εamino group. The AzFP (0.1 mM) was incubated with approximately 0.01 mM HER2-
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Affibody or LDS. The EPL reaction was mixed overnight at room temperature. For the
HER2-Affibody, the EPL product and excess AzFPs were separated on a Superdex 30
chromatography column. For the LDS-peptide, several rounds of washing using Ultracell
3,000 filtration columns were used to remove unreacted AzFP peptides.

Azide functionalization of Cyclic-RGD
Cyclic-RGD was incubated with Azido-dPEG12-NHS at 10:1 molar ratios of
Azide:RGD in DMSO at a final volume of 30 µL. Reactions were incubated at room
temperature overnight and purified via RGD precipitation in 10x volumes of tert-butyl
methyl ether followed by centrifugation at 16,000x g for 1 minute. These precipitations
were performed in triplicate and the resulting conjugate was suspended in a final volume
of 30 µL DMSO.

ADIBO Modification of SPIO NPs for Click Chemistry
Surface amines on SPIO NPs were reacted with the amine-reactive ADIBOdPEG4-NHS in 0.1 M sodium phosphate buffer, pH 9. ADIBO is an alkyne-containing
moiety suitable for click conjugation to the azide-containing ligand preparations.
Specifically, a 138 mM stock of ADIBO-dPEG4-NHS was diluted 100-fold into a 50 µM
solution of SPIO NPs. All nanoparticle solutions were mixed overnight at room
temperature. SPIO NPs were purified via superdex 200 chromatography columns (GE
Healthcare, Piscataway, NJ). The resulting ADIBO-SPIO NPs were incubated with 100
times molar excess of succinic anhydride to convert all remaining amines to carboxyl
groups. ADIBO-SPIO NPs were subsequently purified on superdex200 chromatography
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columns, equilibrated with PBS. For RGD-SPIO and unlabeled SPIO used in flow
cytometry experiments, SPIO NPs were first labeled with a FITC fluorophore (10:1
molar ratio of FITC:SPIO) and purified via PD-10 purification columns before being
labeled with ADIBO.

Copper-Free Click Conjugation
ADIBO-SPIO NPs (1 mg/mL) were mixed with fixed concentrations of HER2AzFP ligand (2.5 20 µM) and LDS-AzFP (30 µM) in PBS, pH 7.4 at a final volume of
100 µL. For RGD-N3, 60 µM of the peptide was incubated with ADIBO-SPIO NPs (1
mg/mL) in a final volume of 100 µL. Reactions were mixed overnight at room
temperature and then purified on Superdex 200 chromatography columns equilibrated
with PBS.

Nanoparticle Physicochemical Characterization
Stock samples of Ln-SPIO nanoparticles were diluted into pH 7.4 phosphate
buffered saline for determination of the hydrodynamic diameter by dynamic light
scattering (DLS) both before and after conjugation to active targeting ligands.
Measurements were acquired with a Zetasizer Nano-ZS (Malvern Instruments,
Worcestershire, UK) using the non-invasive back-scatter (NIBS) mode. For zeta potential
measurements, stock samples of Ln-SPIO were diluted into phosphate buffered saline at
pH 7.4 and then mean nanoparticle zeta potential was measured, both before and after
conjugation to targeting ligands, using a Zetasizer Nano-ZS. For Ln-SPIO nanoparticles,
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the transverse (r2) and longitudinal (r1) relaxivities were measured using a Bruker mq60
tabletop MR relaxometer operating at 1.41 T (60 MHz).

Cell Culture
T6-17 murine fibroblasts (a derivative of the NIH/3T3 line and kindly provided
by Mark Greene, PhD, FRCP, University of Pennsylvania) and HeLa cells (purchased
from ATTC) were cultured and maintained in Dulbecco’s modified Eagle’s medium
(DMEM), supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin
at 37°C and 5% CO2.

Western Blots
T6-17 and HeLa cells were grown to 80% confluence on 10 cm plate. The plate
was washed twice with PBS and then incubated on ice for five minutes in 1mL RIPA
Buffer (Sigma-Aldrich) supplemented with 6M urea. Cells were scraped off the plate and
clarified by centrifugation. 47 mg of solid tumor was solubilized in 3mL Western Lysis
Buffer (12.5mM Tris, 4% SDS, pH 8) with a mortar and pestle. Lysate was boiled for
30min and clarified by centrifugation. Total protein concentrations were determined by
BCA Assay (Pierce). Concentrations of Hsp47, integrin, and ErbB2 were quantified by
Western blot. Specifically, 12.5 uL of each sample was loaded into an Any kD TGX gel
(Bio-Rad) along with four 1:3 serial dilutions. These were quantified on the LiCor
Odyssey and compared against a standard curve ranging from 800 ng to 10 ng of purified
Hsp47 (AbCam), Integrin αVβ3 (R&D Systems), or ErbB2 (OriGene).
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Flow Cytometric Analysis
Cells (T6-17s or HeLas) were dissociated from culture flasks using PBS-based
enzyme free dissociation buffer and transferred to sterile 96-well plates at a final
concentration of 50,000 cells per well. Targeted SPIO conjugates were added to the wells
for 30 minutes at 37°C at a final concentration 75 µg Fe/mL. Cells were transferred to 1.5
mL centrifuge tubes and washed in triplicate by pelleting cells at 1000 RCF for 3 minutes
and then resuspending in PBS. Cells were resuspended in 250 µL of PBS and transferred
to a 96-well plate (50,000 cells per well) and analyzed using a Guava Easycyte Plus
system (Guava Technologies, Hayward, CA). Flow cytometry data were analyzed using
FlowJo software (TreeStar Inc., San Francisco, CA).

Cell Relaxation Studies
T6-17 and HeLa cells were dissociated using PBS-based enzyme free dissociation
buffer and transferred to sterile 48-well plates at a concentration of 3 x 106 cells per well.
Actively targeted SPIO conjugates and unlabeled SPIO were incubated with these cells in
the 48-well plate at a final concentration of 75 µg Fe/mL for 1 hour at 37°C (n=3 for each
targeting agent). Cells were transferred to 1.5 mL centrifuge tubes and washed in
triplicate by pelleting cells at 1,000 RCF for 3 minutes and then resuspending in PBS.
Cells were suspended in a final volume of 300 µL PBS and T2 measurements were taken
using the benchtop relaxometer. The reciprocal of the T2 relaxation time constant, which
represents the MR signal of the cell pellet, was calculated, and the reciprocal of the T2
for cells incubated without nanoparticles (background) was subtracted off. Finally, since
each Ln-SPIO formulation has a different R2 relaxivity value, the MR signal for each cell
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pellet was normalized by dividing by the R2 value of the particular Ln-SPIO used,
resulting in a metric that is proportional to nanoparticle cellular association.

In Vitro ICP-MS Multiplex Assessment of Cell Labeling
T6-17 and HeLa cells were dissociated and incubated with actively targeted SPIO
conjugated and unlabeled SPIO in the same manner as in previous the cell relaxation
studies, with the notable exception that all SPIO formulations were incubated together
with cells, rather than each SPIO formulation being incubated separately. Following
washing to remove unbound nanoparticles, the pellet was resuspended in 100 µL of PBS.
The lanthanide concentration of Ho, Sm, Gd, and Eu was then determined in each pellet
and compared to the concentration present in the incubating medium. Data are plotted as
the ratio of [Ln]pellet / [Ln]incubation medium.

In Vivo Studies
Approximately 6-week old female nu/nu nude mice (Charles River Laboratory,
Charles River, MS, USA) were maintained in accordance with the Institutional Animal
Care and Use Committee of the University of Pennsylvania. Mice were anesthetized via
isoflurane and T6-17 cells were injected subcutaneously into the back right flank (2 x 106
cells in 0.2 mL PBS). Tumors were grown until the diameter was approximately 8 mm.
Ln-SPIO (Ho, Gd, Sm, and Eu) were pooled and injected intravenously at a dose of 3.75
mg Fe / kg body weight. Prior to injection, an aliquot was saved for ICP-MS
determination of lanthanide concentration in injected material. 24 hours after nanoparticle
injection, the animals were sacrificed and the tumors were excised. For each nanoparticle
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formulation, the tumor delivery was calculated as a percent injected dose per gram of
tissue as [Ln]tumor / ([Ln]inj*Minj), where [Ln]tumor is the lanthanide concentration in the
tumor, [Ln]inj is the lanthanide concentration in the injected nanoparticle solution, and
Minj is the mass of nanoparticle solution injected (0.2 grams). For evaluation of “base”
nanoparticles prior to ligand conjugation, one way ANOVA analysis was used to assess
similarity in tumor delivery for the different Ln-SPIO.

4.4 Results and Discussion

Nanoparticle Physicochemical Characterization
Because the size of a nanoparticle formulation influences its
pharmacokinetics and biodistribution, as examined in chapter 2, it was important to
ensure that the four Ln-SPIO formulations exhibit very similar size profiles prior to
targeting ligand conjugation. Therefore, the hydrodynamic diameter of each Ln-SPIO
formulation was determined by DLS prior to conjugation of active targeting ligands. It
was found that the peak of the distribution lay between 27.00 nm and 29.07 nm for all
four formulations (Table 4.1). Furthermore, the size distributions have a very high degree
of overlap (Figure 4.4), suggesting that the “base” nanoparticles to which the active
targeting ligands were attached are very similar populations.
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Table 4.1 Physicochemical properties (hydrodynamic diameter and zeta potential) of LnSPIO formulations before and after conjugation to targeting ligands. Relaxivity values
were measured prior to conjugation and assumed to be unaffected to conjugation.
Dopant

Ligand

Eu
Ho
Sm
Gd

None
HER2-Aff
RGD
LDS

Pre-Conj.
Size nm
27.00
28.07
27.77
29.07

Post-Conj.
Size nm
33.54
33.47
35.57
34.84

Pre Conj.
Zeta mV
-5.63
-4.47
-6.09
-5.77

Post Conj.
Zeta mV
-10.01
-10.53
-6.48
-8.61

R1

R2

6.2
10.3
9.2
8.1

262.9
135.2
158.5
172.6

Figure 4.4 Dynamic light scattering profiles of Ho, Gd, Sm, and Eu doped SPIO
nanoparticles, prior to conjugation with any targeting ligands.
The hydrodynamic diameter of each formulation was subsequently rechecked
after conjugation of active targeting ligands (Figure 4.5). It was found that each
formulation increased in size by approximately 5 nm, so that the post-conjugation sizes
ranged from 33.54 to 35.57. It is likely that the increase in size is due to the addition of
the various functional groups required for conjugation (i.e. ADIBO, linker peptide, and
targeting ligand itself). Again, as before ligand conjugation, the size profiles showed a

119

very high degree of overlap, indicating the populations are very similar in size. This
means it is unlikely that any difference in nanoparticle pharmacokinetics or
biodistribution observed for the actively targeted agents is the result of size alterations
secondary to conjugation.
Next, since it is critical for the ICP-MS multiplex method that the co-injected
nanoparticles do not associate or aggregate with one another prior to injection (as
discussed in chapter 3), DLS measurements were used to rule out the possibility of
nanoparticle aggregation. Specifically, all four Ln-SPIO formulations (post-conjugation)
were mixed together in equal amounts and allowed to incubate together for one hour. The
DLS profile of the mixed solution was then acquired (Figure 4.5). Since the peak size for
the mixed sample was 38.15 nm and the distribution was very similar to that of each
individual formulation, it was concluded that no significant association or aggregation
occurs between the actively targeted formulations prior to injection.
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Figure 4.5 Dynamic light scattering profiles of each nanoparticle formulation after
conjugation to its respective targeting ligand. The size profile was also examined in a
sample where all formulations were combined into a single sample (mixed).

The zeta potential (surface charge) of a nanoparticle formulation also plays a
significant role in the pharmacokinetics and biodistribution of nanoparticle platforms (see
chapter 2). Therefore, the zeta potential of each Ln-SPIO was determined both before and
after conjugation with active targeting ligands. For the “base” nanoparticles, the aminated
nanoparticles (which would display a positive surface charge) were first carboxylated
using succinic anhydride in order to generate a negatively charged surface suitable for
use in the in vivo check on “base” particle similarity (see below). It was found that the
carboxylated “base” nanoparticles had zeta potentials ranging from -4.47 mV to -6.09
mV, which were considered to be very close in value. A slightly greater degree of surface
charge variation was observed in the nanoparticles after conjugation, however (Table
4.1). This is a reasonable expectation, since a number of factors influence what the final
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charge will be (e.g. percentage of amino groups that have undergone conjugation,
percentage of amino groups that have been carboxylated, and the inherent charge of the
targeting ligands). It is worth noting that the inherent charges of the targeting ligands
does not, in itself, explain the small variation seen in surface charge, since at physiologic
pH the charges on the HER2 affibody, RGD, and LDS are expected to be +3, 0, and 0,
respectively. It is possible that these differences in nanoparticle surface charge may
influence the formulations’ blood circulation times, and consequently their tumor
delivery. However, since this small variation in surface charge was introduced through
the process of conjugation, it falls within the realm of what we desire to test: how does
the presence of active targeting ligand effect each nanoparticle’s pharmacokinetics and
biodistribution.
The longitudinal and transverse relaxivities of each Ln-SPIO formulation was also
determined (prior to ligand conjugation) and is reported in Table 4.1. There is significant
variation in the magnetic properties for the four Ln-SPIO formulations, which is not
unexpected since the batch-to-batch variation in magnetic properties is significant for
traditional dextran SPIO without lanthanide dopant. While it is important to know the R2
value for each Ln-SPIO in order to normalize its MR signal during in vitro cell
association assays (see below), agreement between R2 values is not necessary, since MR
imaging is not a primary goal of this investigation. Nevertheless, it is noteworthy that, as
seen in the SPIO synthesized in chapter 2, each Ln-SPIO formulation has significant
magnetic activity. This is helpful since it means that once a set of nanoparticles is
investigated using the ICP-MS multiplex approach, and a particular formulation that
results in greatest tumor delivery has been identified, that specific formulation can then
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be directly administered as a single injection and evaluated for its ability to generate MR
contrast.

In Vivo Equivalence of Nanoparticle Formulations Prior to Conjugation
In order to conclude that differences in tumor accumulation are not due to any
small differences in the physicochemical properties of the SPIO nanoparticles, it is
important to demonstrate that the “base” nanoparticles, prior to ligand conjugation result
in identical tumor delivery. Accordingly, each Ln-SPIO formulation was carboxylated to
confer an equal negative charge to all formulations (see Table 4.1) and the set of
nanoparticles was administered intravenously as a single multiplex injection to T6-17
tumor bearing mice (Figure 4.6).

Figure 4.6 In vivo multiplex ICP-MS analysis of nanoparticle accumulation in T6-17
tumors (expressed as percent injected dose / gram of tumor tissue) for carboxylated LnSPIO before conjugation to active targeting ligands. ANOVA analysis yielded an F ratio
of 0.594, corresponding to a P value of 0.636
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It was found that the tumor delivery for the four Ln-SPIO formulations ranged
from 0.99 to 1.22 percent injected dose / gram of tumor tissue. One way analysis of
variance (ANOVA) statistical testing demonstrated a P value of 0.594, indicating that
there is no evidence of any meaningful difference in tumor delivery for any formulation
within the set. Since ANOVA testing does not utilize the pairing information contained in
multiplex data, a simple t-test (with pairing) was also conducted between the nanoparticle
with lowest accumulation (Eu) and the one with highest accumulation (Ho). This yielded
a P value of 0.16; again suggesting that even with the improved statistical power of
paired analysis, there is no significant difference between the nanoparticle formulations at
“baseline”.

Assessment of Biomarker Expression by Western Blot
In order to assess the level of receptor expression for the three biomarkers
investigated in this study, Western blots were conducted on T6-17 cells, HeLa cells, and
excised T6-17 tumors. The blot images are provided in Figure 4.7.

Figure 4.7 Western Blots of T6-17 cells, HeLa cells, and excised T6-17 tumor tissue,
probing for HER2, αVβ3 integrin, and Hsp47.
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First, it was found that the level of HER2 (ErbB2) expression on T6-17 cells was
very high and significantly greater than the level of expression on HeLa cells. Given that
T6-17 cells are NIH-3T3 murine fibroblasts engineered to constitutively overexpress
HER2, this result is expected. The relative abundance of HER2 protein in the excised T617 tumor appears lower than T6-17 cells in vitro. It is possible that this is due to an
alteration of HER2 expression of the T6-17 cells once organized into a tumor, but it is
more likely that the relative abundance of HER2 is lower as a result of the large amount
of non-T6-17 cell derived protein in the tumor (e.g. stromal cells and extracellular matrix
proteins). Nevertheless, HER2 expression was still clearly evident in the excised T6-17
tumor lysate.
Next, the level of αVβ3 integrin was examined. It was found that the level of
expression of this biomarker was again higher in T6-17 cells compared to HeLa cells,
although the degree of difference was much less than with the HER2 receptor. Studies
have shown integrin αVβ3 expression in NIH/3T3 cells and this expression appears to be
conserved in T6-17 cells.38, 39 Interestingly, unlike the HER2 receptor relative abundance,
which drops once the entire tumor is examined, the αVβ3 integrin levels are higher in the
excised T6-17 tumor compared to the individual cells. This is likely because αVβ3
integrin is highly overexpressed on activated endothelial cells associated with the
neovascularization of tumors.40-42 In fact, previous reports have shown that in tumor
xenograft models αVβ3 integrin can be overexpressed both on the malignant cells,
themselves, and on host-derived proliferating endothelial cells.43 This makes αVβ3
integrin a particularly interesting biomarker to compare with HER2. Specifically, even
though HER2 is more abundant on tumor cells than αVβ3 integrin, targeting αVβ3 integrin
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might result in increased tumor delivery, since it is expressed elsewhere in the tumor
tissue. Importantly, this is a comparison that can only be adequately made in vivo,
demonstrating the utility of being able to use ICP-MS for multiplex analysis in vivo.
Finally, levels of Hsp47 were examined. In this case, the expression of this
biomarker was below the level of detection for both T6-17 and HeLa cells. Although
there is little literature regarding the expression of Hsp47 on these two cells lines, it is not
surprising to observe very low levels of expression since Hsp47 is most commonly
associated with head and neck or gastrointestinal malignancies.27, 29, 44,
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Interestingly,

however, Hsp47 expression was clearly detectable in the excised T6-17 tumor. There are
two potential possibilities to account for this observation. First, it is known that Hsp47
expression is upregulated during a cellular stress response to noxious stimuli including
high temperature, heavy metal exposure, and oxidative stress.46 Since the establishment
of a rapidly growing xenograft tumor is likely to be associated with a hostile local
environment, it is possible that the T6-17 cells themselves are upregulating their
expression of Hsp47. Alternatively, cell populations within the tumor other than the T617 cells themselves may be displaying the biomarker. In either case, this again illustrates
the idea that evaluating active targeting of Hsp47 directed nanoparticles is best done fully
at the in vivo stage, since expression profiles of the tumor are not the same as those in
vitro.
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Flow Cytometric Analysis of Targeted Ln-SPIO

The functionality of HER2-SPIO, LDS-SPIO and RGD-SPIO was subsequently
assessed by conducting cell-binding assays with the broadly “receptor high” T6-17 cells
and broadly “receptor low” HeLa cells. Flow cytometric analysis revealed that each
targeted SPIO formulation successfully labeled T6-17 cells to varying extents, with the
HER2-SPIO showing the highest degree of cell labeling and the LDS-SPIO showing the
lowest (Figure 4.8 A). This is generally consistent with the results of the Western blots in
that strong labeling was observed for the highly expressed HER2 receptor, and a lower
level of labeling was observed for the less highly expressed αVβ3 integrin. Although
Hsp47 expression was not detectable on Western blots of T6-17 cells, flow analysis is
likely to be more sensitive given that each nanoparticle carries multiple fluorophores,
thereby amplifying the signal. Eu-SPIO nanoparticles that have been reacted with
ADIBO and carboxylated with succinic anhydride, but have no targeting ligand
conjugated to them, showed no cell binding when incubated with T6-17 cells (Figure 4.8
B).
Based on the relative level of receptor expression between T6-17 and HeLa cells,
a lower level of cell binding for each ligand is expected on HeLa cells, compared to T617 cells. The flow cytometric data bear this out in the most general sense, with
undetectable cell binding of each targeted SPIO formulation to the broadly “receptor
low” control HeLa cells (Figure 4.8 C). However, since flow cytometric measurements
should have high sensitivity, we would expect that at least a low level of cell binding
should be observed. Additionally, as expected, no cell binding was detected when
unlabeled SPIO nanoparticles were incubated with HeLa cells (Figure 4.8 D).
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Figure 4.8 Flow cytometric analysis of “receptor positive” (T6-17) and “receptor high”
(HeLa) cells incubated with SPIO nanoparticles. T6-17 cells were incubated with HER2SPIO (light solid line), RGD-SPIO (dashed line), and LDS-SPIO (dotted line), with
varying degrees of cell labeling observed for each ligand (A). No cell labeling is evident
for the “receptor low” HeLa cells for any of the ligands (C). Additionally, flow
cytometric analysis was performed for both cell lines incubated with non-targeted SPIO
and no cell labeling was detected (B and D).
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MR Comparison of Cell Binding
In vitro cell binding assays were also carried out by incubating targeted SPIO
conjugates with T6-17 or HeLa cells for 1 hour at a final concentration of 75 µg/mL Fe
and examining the T2 relaxivity of cell pellets. This assay provided a more reliable
measurement for the comparison of cell binding between ligands than flow cytometry
does, since the fluorescence signal per nanoparticle is not expected to be the same for
each formulation. For the MR assay, comparison of the level of cell labeling was made
by using the reciprocal of the T2 relaxation time of the cell pellet as a measure of MR
signal. The signal was adjusted by the R2 of the particular Ln-SPIO formulation used
(e.g. Ho-SPIO for the affibody) to yield a normalized MR signal.
These data follow the same general trend as observed with the flow cytometric
analysis. HER2 affibody conjugated SPIO exhibit an extremely high level of cell labeling
on T6-17 cells and much lower labeling on HeLa cells (Figure 4.9). Again, it was not
surprising that the HER2-SPIO displayed the highest degree of cell binding, since T6-17
cells have been transfected to overexpress the HER2/neu receptor.47 RGD-SPIO exhibit
approximately half the level of cell labeling (compared to HER2-SPIO) on T6-17 cells,
but the level of labeling is clearly well above baseline nonspecific interactions observed
with blank-SPIO. This level of labeling is also statistically greater than the very low level
of labeling observed for RGD-SPIO of HeLa cells. Finally, while both cell lines exhibited
a very low level labeling with LDS-SPIO, although even this low level of cell binding
can be distinguished from the nonspecific binding of blank-SPIO.
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Figure 4.9 Labeling of T6-17 and HeLa cells with Ho-HER2-SPIO, Sm-RGD-SPIO, GdLDS-SPIO and Eu-blank-SPIO, as assessed by MR relaxometry. Since each Ln-SPIO has
different magnetic relaxivity, the T2 relaxation signal obtained for each cell pellet was
normalized by the R2 value of the SPIO formulation and reported as a relative value to
the signal of the blank formulation.

ICP-MS Comparison of Cell Binding
Finally, an ICP-MS in vitro cell binding assay was conducted by simultaneously
incubating all targeted SPIO conjugates with T6-17 or HeLa cells for 1 hour at a final
concentration of 75 µg/mL Fe and analyzing the lanthanide concentration of the washed
cell pellets versus the lanthanide concentration in the incubating medium (Figure 4.10).
This assay is expected to provide the most reliable data for making comparisons, both
between ligands and between cell lines, for three reasons. First, each nanoparticle
formulation’s binding can be quantitatively normalized to the amount of material applied
to the cells in the assay. Secondly, unlike the MR based assay, the “signal” detected by
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ICP-MS is linear over a very large dynamic range of nanoparticle concentrations. This is
especially important at low levels of nanoparticle binding, when ICP-MS can detect
differences in binding that would not translate into a difference in MR signal. Thirdly,
since this assay multiplexes the measurement of cell binding, many sample-to-sample
variations (such as non-specific uptake by dead cells) are eliminated.

Figure 4.10 Labeling of T6-17 and HeLa cells with Ho-HER2-SPIO, Sm-RGD-SPIO,
Gd-LDS-SPIO and Eu-blank-SPIO, as assessed by ICP-MS multiplex analysis. All
targeted nanoparticle formulations were pooled together and incubated with either T6-17
or HeLa cells in the presence of serum supplemented culture medium.

The ICP-MS multiplex data again bear out the same general conclusions as the
flow cytometric and MR-based assays. First, for each ligand, the level of binding to the
“receptor high” T6-17 cells is greater than the level of binding to the “receptor low”
HeLa cells. Secondly, with respect to T6-17 cell binding, HER2-SPIO demonstrate the
greatest level of cell labeling, followed by RGD-SPIO, and LDS-SPIO, all of which are
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distinguishable from the non-specific of blank-SPIO. The major difference that the ICPMS cell labeling data suggest is with regard to the absolute level of nanoparticle binding
to HeLa cells. In the flow cytometric and MR analysis, there was very little cell binding
observed for any of the ligands to HeLa cells. However, based on the Western blots, it
can be concluded that while the HeLa cells are “receptor low” compared to T6-17 cells,
they do not appear to be “receptor negative”. This discrepancy may be partly accounted
for by the differences in sensitivity and signal linearity between the different modalities.
Nevertheless, it appears that the flow cytometric results, which should provide a high
level of sensitivity, will require further investigation in order to ensure the four sets of in
vitro measurements are all properly reconciled.

4.5 Conclusion
It is possible to synthesize SPIO nanoparticles, doped with a variety of lanthanide
tracer metals, each with an overlapping size distribution, so that they exhibit equal levels
of passive tumor accumulation. These Ln-SPIO formulations can then be subsequently
functionalized with active targeting ligands, such that each targeting ligand is associated
with a specific lanthanide tracer. ICP-MS analysis can quantify the concentration of each
lanthanide metal independently and with very high sensitivity, in a single fluid or tissue
sample. Therefore, it becomes feasible to collect nanoparticle blood residence time,
tumor delivery, and biodistribution for many actively targeted and negative control
formulations in a single animal. This represents a powerful tool for nanotechnology
investigators to more thoroughly evaluate a greater number of nanoparticle formulations
in vivo, while reducing experiment time, cost, and number of animals.
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Chapter 5: pH Titratable Superparamagnetic Iron Oxide for
Improved Nanoparticle Accumulation in Acidic Tumor
Microenvironments

5.1 Abstract
A wide variety of nanoparticle platforms are being developed for both the diagnosis
and treatment of malignancy. While many of these are either passively targeted or rely on
specific receptor-ligand interactions, metabolically directed nanoparticles can provide a
complementary approach. It is known that both primary and secondary events in
tumorigensis alter the metabolic profile of developing and metastatic cancers. One highly
conserved metabolic phenotype is a state of up-regulated glycolysis and reduced use of
oxidative phosphorylation, even when oxygen tension is not limiting. This metabolic
shift, termed the Warburg effect, creates a “hostile” tumor microenvironment with
increased levels of lactic acid and low extracellular pH. In order to exploit this
phenomenon to improve the delivery of nanoparticle platforms to a wide variety of
tumors, a pH-responsive iron oxide nanoparticle was designed. Specifically, glycol
chitosan (GC), a water-soluble polymer with pH titratable charge, was conjugated to the
surface of superparamagnetic iron oxide nanoparticles (SPIO) to generate a T2* weighted
MR contrast agent that responds to alterations in its surrounding pH. When compared to
control nanoparticles that lack sensitivity to pH, these GC-SPIO nanoparticles
demonstrated potent pH-dependent cellular association and MR contrast in vitro. In
murine tumor models GC-SPIO also generated robust T2* weighted tumor contrast,
which correlated with increased delivery of the agent to the tumor site, as measured
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quantitatively by inductively coupled plasma mass spectrometry. Importantly, the
increased delivery of GC-SPIO nanoparticles cannot be attributed to the commonly
observed enhanced permeability and retention effect alone, since these nanoparticles have
similar physical properties and blood circulation times as control agents.

141

5.2 Introduction
Tumor targeting mechanisms that exploit the altered metabolic profile of malignancy
have been the subject of intense investigation1 since the development of the metabolite
analogue 2-fluorodeoxy-D-glucose (2FDG) and its use in positron emission tomography
(PET) imaging over three decades ago.2 One of the attractions of metabolic imaging is
the ability to detect and target a wide variety of cancers, since many human solid tumors,
and especially rapidly growing aggressive malignancies, have a unique metabolic profile
that distinguishes them from normal tissue.3 This altered metabolic state, consistent with
the Warburg effect, is characterized by increased glucose uptake, up-regulated glycolytic
metabolism, increased production of lactic acid, and subsequent derangements in cellular
pH.4, 5 More specifically, the extracellular pH of normal tissue is approximately 7.4, but
human and animal tumors can often exhibit an extracellular pH lower than 7.0, even
reaching as low as 6.3.6, 7
In recent years, numerous methods have been developed that allow for the noninvasive assessment of tissue pH, most of which are based on magnetic resonance.6 For
example, magnetic resonance spectroscopy (MRS) using endogenous inorganic
phosphate (Pi) and exogenously administered 3-aminopropylphosphate (3-APP) can be
used to simultaneously measure intra- and extracellular pH, respectively.8,

9

Major

drawbacks of this method are the reliance on the relatively less abundant 31P nucleus and
the inability to simultaneously acquire the high resolution anatomical information that is
the hallmark of magnetic resonance (MR) imaging. More recently, exogenous agents
with pH-dependent proton resonances have been developed.10 While this eliminates the
need for specialized

31

P hardware, the pH sensitive resonance can be difficult to fully

distinguish from other endogenous signals. Even more recently, pH-sensitive lanthanide
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chelates have allowed for measurement of pH with a proton resonance completely
distinct from endogenous signals.11,

12

Even these agents, however, have limited

sensitivity since the exogenous agent contains the resonance being detected. Greater
sensitivity could be obtained using a contrast agent that generates signal by interacting
with many bulk water molecules. Superparamagnetic iron oxide (SPIO) nanoparticles
have emerged as an attractive class of MR contrast agent that provides T2*-weighted
contrast enhancement in both active and passive MR imaging applications by
accelerating the de-phasing of nearby bulk water.13 SPIO nanoparticles could, therefore,
serve as a strong signal-generating foundation to which pH sensitivity could be imparted.
Such pH-responsive SPIO nanoparticles would constitute an 1H MR contrast agent that
exhibits differential localization based on local pH and could facilitate the detection of
acidic pathologies, including but not limited to malignancy, on conventional high
resolution anatomic MR images, without the need for specialized hardware. Such regions
of suspected acidity, detected with pH-responsive SPIO on large field-of-view anatomic
images, could then be probed by MRS or chemical exchange saturation transfer (CEST)
methods to generate an absolute pH map.
pH-responsive

polymers,

including

chitosan,14

poly-amino

ester,15

poly-

caprolactone,16 and poly-histidine,17 have been successfully used to generate pHmediated drug release in a variety of nanoparticle carriers. Furthermore, SPIO
nanoclusters coated with a pH-responsive hydrogel have recently yielded nanoparticles
with pH-dependent relaxivity.18 Therefore, pH-titratable polymers are attractive
candidates for imparting such functionality to nanoparticles. Accordingly, in this
investigation, the pH-responsive polymer glycol chitosan (GC, Figure 5.1 A), a polymer
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of glucosamine with increased water solubility and amino groups with a pKa ≈ 6.5,19 was
covalently grafted to the surface of dextran stabilized SPIO nanoparticles, to generate
native GC-SPIO. Sized matched pH-unresponsive SPIO nanoparticles were prepared as
control agents to distinguish pH-mediated nanoparticle delivery from the enhanced
permeability and retention (EPR) effect that is commonly observed for nanoparticle
agents.20-23 Specifically, GC-coated SPIO nanoparticles were chemically modified with
glycidol (Figure 5.1 B) to block the pH-responsive amino groups, and inherently pHunresponsive dextran SPIO nanoparticles (Figure 5.1 C) were also used.

Figure 5.1 Molecular structures of nanoparticle polymeric surface coatings. (A) Native GC is a
linear polymer of D-glucosamine with β-1-4 linkages. The repeated amino groups have aggregate pKa ≈
6.5. (B) Glycidol blocked GC is formed by reaction of native GC with glycidol. Alkylation of the amino
groups renders them no longer titratable near physiologic pH. (C) Dextran is a branched polymer of glucose
with both α-1-3 and α-1-3 linkages. It does not possess any functional groups that are titratable near
physiologic pH.
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All nanoparticle formulations included a lanthanide metal tracer that allowed the
distribution of the nanoparticles to be tracked quantitatively in vivo. Specifically, during
the synthesis of the SPIO nanoparticles, a trace amount of lanthanide was doped into the
iron oxide cores (Gd for the two GC-containing SPIO formulations and Sm for the
dextran-only SPIO). Energy-dispersive X-ray spectroscopy (EDS) has previously been
used to confirm the presence and stability of the lanthanide dopant within the iron oxide
cores of SPIO synthesized in this manner.24 Here, inductively coupled plasma mass
spectrometry (ICP-MS) was used to assess the biodistribution of the lanthanide tracer
(and the corresponding SPIO nanoparticle) in a mouse tumor model.
Numerous studies have shown that nanoparticles (including SPIO) complexed with
cationic agents such as polylysine, protamine, or cell penetrating peptides (CPPs) are
rapidly and efficiently internalized by a wide range of cell types.25-28 However, positively
charged nanoparticles are rapidly cleared from circulation,29 resulting in poor tumor
delivery. Therefore, positive charge could be used to improve retention in a desired
microenvironment, provided that the positive charge is not displayed until that
microenvironment is reached. Accordingly, both the native GC-SPIO and control agents
exhibit a neutral or negative surface charge at physiologic pH, affording them a lower
level of cellular interaction and improving blood residence time.30,

31

(Figure 5.2 A).

Upon exposure to an acidic mircroenvironment, the pH-responsive polymer surface of the
native GC-SPIO becomes protonated and the surface charge becomes increasingly
positive. Therefore, it was hypothesized that native GC-SPIO nanoparticles would be
preferentially retained in acidic microenvrionments compared with analogous pH-
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unresponsive agents, as a result of electrostatic interactions with surrounding tissue
(Figure 5.2 B).

Figure 5.2 Mechanism of enhanced nanoparticle retention in acidic microenvironments. (A) Both native
GC-SPIO and control nanoparticles exhibit neutral to negative surface charge at physiologic pH due to
abundant surface hydroxyl groups. For clarity, the hydroxyl groups are not depicted on the native GC-SPIO
particle. Presence of neutral or negative surface charge diminishes nanoparticle association with blood
components and normal tissue. (B) Upon exposure to acidic microenvironments, the amino groups of
native GC-SPIO titrate to yield a positive charge. The newly cationic nanoparticles exhibit electrostatic
interactions with negatively charged cell membranes and extracellular matrix components in the acidic
microenvironment, leading to enhanced retention in these areas.

5.3 Materials and Methods
Materials
The two SPIO coating polymers dextran T10 and glycol chitosan were purchased
from Pharmacosmos A/S (Holbaek, Denmark) and Wako Chemicals (Richmond, VA,
USA), respectively. T6-17 murine fibroblasts (a derivative of the NIH/3T3 line) were
kindly provided by Mark Greene, PhD, FRCP, at the University of Pennsylvania. The 35
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mm volume coil used for radiofrequency transmission and reception was purchased from
Insight Neuroimaging Systems, LLC (Worcester, MA). All other reagents were
purchased from Sigma Aldrich USA unless otherwise noted.

Synthesis of Dextran Stabilized Lanthanide Doped SPIO
Dextran coated, lanthanide doped, SPIO nanoparticles were prepared though the
coprecipitation of ferrous, ferric, and lanthanide ions in the presence of dextran.24,

28

Briefly, 50 g of dextran T-10, was dissolved in 100 mL dH2O and heated to 80°C for 1
hour. The solution was then allowed to cool to room temperature and continued to mix
overnight. Subsequently, a solution of 3.70 g FeCl3, 1.46 g FeCl2, and 0.25 g
GdCl3•6H2O or SmCl3•6H2O in 50 mL dH2O was prepared and decanted into the dextran
solution. The combined solution was cooled on ice and degassed with N2 for 90 min.
While keeping the solution stirring on ice and under N2, an automated syringe pump was
then used to introduce 15 mL of concentrated NH4OH to the solution over 5 hours. The
resulting black viscous solution was removed from the N2 atmosphere, heated to 90°C for
1 hour, cooled overnight, and centrifuged at 20,000 RCF for 30 minutes to remove large
aggregates. Free iron, lanthanide, and dextran were removed by diafilitration across a 100
kDa membrane and the dextran SPIO were brought to a final volume of 40 mL.
Surface Conjugation of Glycol Chitosan
High molecular weight glycol chitosan was degraded and prepared for grafting to
dextran SPIO as follows: 10 g of ≈600 kDa GC was dissolved in 200 mL 6M HCl and
heated to 80°C for 20 minutes. Following incubation, the material was cooled on ice and
immediately neutralized with the addition of solid sodium carbonate to terminate
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degradation. Excess solid sodium carbonate was removed by centrifugation and
diafiltration membranes were used to de-salt the material and discard any GC polymer
greater than 100 kDa or less than 3 kDa.
Native glycol chitosan (GC)-SPIO was then prepared as follows: 40 mL of dextran
SPIO at an iron concentration of 10 mg/mL was combined with an equal volume of 10 M
NaOH and mixed for 10 minutes. 80 mL of epichlorohydrin was then added and the
solution was vigorously stirred at room temperature overnight. Epichlorohydrin
crosslinks dextran chains within a SPIO particle and chemically activates the dextran
surface for grafting of glycol chitosan. The solution was then briefly centrifuged to allow
phase-separation into an aqueous black SPIO layer and a clear layer of unreacted
epichlorohydrin, which was removed. The SPIO layer was quickly purified via extraction
in isopropanol. Specifically, the SPIO material was combined with 5 volumes of
isopropanol and the mixture was vigorously shaken. Brief centrifugation of the mixture
resulted in a layer of precipitated salt, a SPIO layer, and an isopropanol layer (containing
any remaining epichlorohydrin). The SPIO layer was then isolated and combined with an
equal volume of 150 mg/mL GC (3 – 100 kDa) in PBS, and gently stirred for 72 hours at
room temperature. After the reaction, free GC was removed by diafiltration across a 100
kDa membrane and the final native GC-SPIO was 0.2 µm filtered to remove any
oversized material. Finally, to ensure complete purification of the GC-SPIO from excess
GC and to enhance the material’s magnetic properties, the nanoparticles were
magnetically purified on MACS LS columns using the MidiMACS magnet (Miltenyi
Biotec, Auburn, CA, USA).
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Generation of Control SPIO Nanoparticles
Glycidol GC-SPIO control nanoparticles were produced by direct chemical
modification of the native GC-SPIO nanoparticle surface. Briefly, native GC-SPIO at 5
mg Fe/mL in 10 mM pH 5.0 HEPES buffer was combined with an equal volume of
glycidol and stirred at room temperature overnight. GC-SPIO was then precipitated from
the solution by the addition of 4 volumes of isopropanol. Since the blocking was
incomplete after only one round of reaction with glycidol, the addition at 0.2 volumes of
7.5% sodium bicarbonate was sometimes required to neutralize remaining positive charge
on the nanoparticle surface and induce precipitation. The solution was centrifuged, the
supernatant discarded, and the GC-SPIO pellet was resuspended with sonication in the
original volume of HEPES buffer. Reaction with glycidol was repeated as above 2 more
times to exhaustively block pH responsive amino groups (subsequent reactions do not
require bicarbonate to induce precipitation in isopropanol). Finally, sized matched
dextran SPIO were used as a second pH-unresponsive control nanoparticle formulation.
In order to best match the size of the dextran SPIO control nanoparticles to the GC
grafted nanoparticles, the dextran SPIO nanoparticles used as a control were not from the
same synthesis as the dextran SPIO upon which the GC grafted nanoparticles were
constructed. Specifically, the rate of NH4OH addition was increased in order to produce
somewhat larger size dextran SPIO.
Native GC-SPIO and Control Nanoparticle Physicochemical Characterization
Each nanoparticle formulation was diluted to a final concentration of 100 µg
Fe/mL in pH 7.4 phosphate buffered saline for determination of the hydrodynamic
diameter by dynamic light scattering (DLS). Measurements were acquired with a
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Zetasizer Nano-ZS (Malvern Instruments, Worcestershire, UK) using the non-invasive
back-scatter (NIBS) mode. Samples were further diluted in water and deposited on 200mesh carbon coated copper grids (Polysciences, Warrington, PA, USA) for TEM imaging
with a JEOL 1010 transmission electron microscope operating at 80 kV. Mean iron core
size was determined by measuring 100 individual nanoparticles. The transverse (R2) and
longitudinal (R1) relaxivities of the nanoparticle formulations were calculated by plotting
the reciprocal of the relaxation time (measured using a Bruker mq60 tabletop MR
relaxometer operating at 1.41 T) versus the iron concentration. For elemental analysis,
nanoparticles were precipitated with isopropanol, dried under vacuum, and submitted to
Intertek Analytical Laboratories (Whitehouse, NJ, USA). Since glycol chitosan is the
only nitrogen containing component of the nanoparticles, the %N of the sample can be
scaled to %GC, using the empirical formula of glycol chitosan, C8H15O5N. Similarly,
since dextran is the only carbon containing component (after the carbon content of GC is
accounted for), the %dextran can be calculated using its empirical formula, C6H10O5. For
zeta potential pH titrations, 10 mM HEPES buffered water was prepared with pH values
ranging from 5.90 to 7.65 in 0.25 unit increments. Each nanoparticle formulation was
diluted to a final concentration of 100 µg Fe/mL in the buffer at each pH and mean
nanoparticle zeta potential was measured using a Zetasizer Nano-ZS. Stocks of native
GC-SPIO, glycidol GC-SPIO, and dextran SPIO were synthesized several times
throughout the course of the study, each time yielding similar physicochemical
properties.
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Cell Culture
T6-17 murine fibroblasts were cultured and maintained in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin at 37°C and 5% CO2.

In Vitro Cellular Association Studies
For in vitro pH studies, cell culture medium was supplemented with 25 mM
HEPES buffer and prepared with pH values ranging from 5.90 to 7.65 in 0.25 unit
increments. Each nanoparticle formulation was incubated in suspension at a
concentration of 25 µg Fe/mL with 4 x 106 of freshly trypsinized T6-17 cells for 1 hour at
37°C in a total volume of 0.5 mL buffered medium. Following incubation, unassociated
nanoparticles were removed by triplicate low-speed centrifugal washes with nanoparticle
free medium of matching pH. The cell samples were then resuspended in 0.3 mL of PBS
at pH 7.4 and the T2 relaxation time of the suspensions were measured on the tabletop
relaxometer.

Cell Pellet MR Imaging
Following relaxation measurements, the triplicate samples at each pH were
combined to form a single cell pellet for each pH and nanoparticle formulation. The
samples were transferred to a 384-well plate and the cells were pelleted to the bottom of
each well with brief, low-speed centrifugation. The plate was then imaged on a 9.4-T
magnet interfaced to a Varian INOVA console using a 70 mm inner diameter volume coil
for radiofrequency transmission and reception. T2*-weighted gradient echo (GEMS) MR
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images were collected using parameters as follows: repetition time (TR) = 200 ms, echo
time (TE) = 5 ms, flip angle = 20°, slice thickness = 0.5 mm, field of view (FOV) = 4 cm
x 4 cm, number of acquisitions = 8, resolution = 256 x 256.
Contrast Enhanced In Vivo MR Imaging
Approximately 6-week old female nu/nu nude mice (Charles River Laboratory,
Charles River, MS, USA) were maintained in accordance with the Institutional Animal
Care and Use Committee of the University of Pennsylvania. Mice were anesthetized via
isoflurane and T6-17 cells were injected subcutaneously into the back right flank (2 x 106
cells in 0.2 mL PBS). Tumors were grown until the diameter was approximately 8 mm
and pre-contrast tumor images were acquired using a 9.4-T magnet interfaced to a Varian
INOVA console. T2*-weighted GEMS images were collected using the same parameters
as for plate images, except slice thickness = 1 mm. Immediately following the precontrast image acquisition, native GC-SPIO or control nanoparticles were administered
by retro-orbital injection (10 mg/kg Fe in 0.2 mL; Native GC-SPIO n=4, glycidol GCSPIO n=4, dextran SPIO n=3). Post-contrast images were collected 24 hours postinjection under the same imaging parameters used for pre-contrast images.
MR Image Analysis
For each animal’s pre- and post-contrast image, three corresponding axial slices
were selected for analysis. To account for signal variations between images due to mouse
or RF coil positioning, the relative signal intensity (RSI) of the tumor in each slice was
calculated by dividing the MR signal of the operator defined tumor region of interest
(ROI) by that of the adjacent paraspinal muscle. Nanoparticle induced tumor contrast was
then determined as the RSI ratio for each animal, calculated as the quotient of the post152

contrast tumor RSI to the pre-contrast tumor RSI. Following statistically significant
ANOVA analysis for the three nanoparticles’ contrast, individual t-tests were performed.
Quantitation of Tumor Delivery and Blood Concentration by ICP-MS
Prior to nanoparticle injection, an aliquot of nanoparticles from each group of
mice was saved for inductively coupled plasma mass spectrometry (ICP-MS)
determination of lanthanide concentration (Gd for native and glycidol GC-SPIO and Sm
for dextran SPIO). Following nanoparticle injection, 10 µL blood samples were collected
from each animal, using the tail-nick method, at times of 1, 2, 4, 7, and 24 hours postinjection. Following post-contrast MR imaging, the animals were sacrificed and the
tumors, livers, and kidneys excised.
For ICP-MS analysis, analytical standards were purchased from SCP (Champlain,
NY, USA) and trace metal grade nitric acid was purchased from Fisher Scientific
(Pittsburg, PA, USA). All dilutions were done using in-house deionized water (≥18 MΩcm) obtained from a Millipore water purification system.
The pre-injection solutions, blood, and tumor samples were analyzed for
(gadolinium), or
CT, USA)
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Gd
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Sm (samarium) using an Elan 6100 ICP-MS (Perkin Elmer, Shelton,

at the New Bolton Center Toxicology Laboratory, University of

Pennsylvania, School of Veterinary Medicine, Kennett Square, PA, USA. The samples
were weighed into Teflon PFA vials (Savillex, Minnetonka, MN, USA) and digested
overnight with 70% nitric acid at 700 C. 0.1 mL of 2 ppm 159 Tb (terbium) was added to
each of the digested samples and the mixtures were diluted with deionized water to a
final volume of 10 mL. The lanthanide concentration of each sample was measured using
a calibration curve of aqueous standards at 0.01, 0.1, 1.0, and 10 ppb for each lanthanide.
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The performance of the instrument and accuracy of the results were monitored by
analyzing a reagent blank and bovine serum control serum prior to analysis of the
samples. Also, standard reference material (Peach Leaves 1547) obtained from National
Institute of Standards and Technology (NIST, Gaithersburg, MD, USA) with known
values of iron and rare earth elements was analyzed with each batch of samples.
The percent injected dose per gram of tissue, was calculated as [Ln]sample /
([Ln]inj*Minj) where [Ln]sample is the lanthanide concentration in the sample (blood or
tumor tissue), [Ln]inj is the lanthanide concentration in the injected nanoparticle solution,
and Minj is the mass of nanoparticle solution injected (0.2 grams). For tumor, kidney, and
liver accumulation, ANOVA analysis was performed for the three nanoparticle
formulations. Where differences were detected (tumor and kidney), individual t-tests
were performed.

5.4 Results and Discussion
Characterization of Native GC-SPIO and Control Nanoparticles
Since previous studies have identified that the blood circulation times20-23 and,
consequently, tumor delivery is highly dependent on the size of SPIO nanoparticles, the
hydrodynamic diameter of the native GC-SPIO and control nanoparticles (i.e. glycidol
GC-SPIO, and dextran SPIO) was characterized by dynamic light scattering (DLS). Also,
because of the need to distinguish pH-mediated delivery from a background level of EPR
delivery, it was necessary to ensure that the native GC-SPIO and control nanoparticles
had very similar size profiles. The peak sizes of the native GC-SPIO, glycidol GC-SPIO,
and dextran SPIO were found to be 33.6 nm, 36.1 nm, and 29.8 nm, respectively. Since
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the glycidol GC-SPIO particles were synthesized by direct chemical blockade of the pH
sensitive amino groups of the native GC-SPIO, the glycidol GC-SPIO are necessarily
slightly larger (2.5 nm). Although the size of dextran SPIO can be marginally tuned with
varied synthetic conditions, these particles are necessarily slightly smaller (3.8 nm) than
the native GC-SPIO, owing to the latter’s additional GC coating. Given the close
agreement in peak sizes and DLS size distributions (Figure 5.3) for the three nanoparticle
formulations, it is assumed that differences in tumor delivery can be attributed to
differences in the chemistry of their surface coat, as opposed to their hydrodynamic
diameter.

Figure 5.3 Dynamic light scattering profiles of native GC-SPIO, glycidol GC-SPIO, and dextran
SPIO nanoparticles in phosphate buffered saline, pH 7.4.
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In order to examine the morphology of the iron cores of the nanoparticle
formulations, and ensure their similarity, transmission electron micrographs (TEM) were
obtained (Figure 2B). The average core sizes of the GC-based SPIO and dextran SPIO
were found to be 19.8 ± 3.6 nm, and 19.4 ± 3.9 nm, respectively. Since only the surface
coating was modified between the native GC-SPIO and glycidol GC-SPIO, these two
formulations have matching core size characteristics. The morphology of iron cores
appears similar for all three nanoparticle formulations and similar to previously published
dextran SPIO images.28

Figure 5.4 Transmission electron microscopy (TEM) images of GC-SPIO and dextran SPIO
demonstrating iron core size and morphology.

The metal and polymer composition of the native GC-SPIO nanoparticles was further
examined by elemental analysis. Dried nanoparticles were 37.05% C, 2.87% N, 6.09%
Fe, and 0.17% Gd by weight. Since only GC contains nitrogen, these data and the known
molecular structure of dextran and GC allow for calculation of nanoparticle composition.
The native GC-SPIO nanoparticles are, therefore, 6.09% iron, 0.17% gadolinium, 39.08%
dextran, and 42.02% glycol chitosan. The remainder of the nanoparticles (12.67%) is a
combination of oxygen in the nanoparticle core and any electrostatically associated salts.
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Although comparison of tumor delivery via ICP-MS measurements is not
influenced by the nanoparticles’ magnetic properties, the comparison of in vivo MR
tumor contrast certainly is. Therefore, it was important to ensure all three nanoparticle
formulations had similar values for their relaxivities, especially the R2 relaxivity, which is
responsible for contrast enhancement on T2* weighted MR images. R2 values (pH 7.4,
PBS) for the native GC-SPIO, glycidol GC-SPIO and dextran SPIO were measured as
146.5, 152.3, and 150.4 Fe mM-1 s-1, respectively. The native GC-SPIO demonstrated
only a minor increase in R2 relaxivity (≈ 5%) as the pH decreased to 5.9, while the
glycidol GC and dextran SPIO had no pH dependence to their R2 values. Although
improved relaxivity for the native GC-SPIO at low pH values can further improve pH
mediated contrast, this is not the primary mechanism by which contrast is generated.
Rather, titration of the native GC-SPIO surface coat leads to greater accumulation of
nanoparticles at the tumor. Given the R2 values for all three formulations were very
similar at physiologic pH, it was concluded that there is no contrast bias for the native
GC-SPIO.Finally, the surface charge (zeta potential), and its pH dependence, was
examined for each of the nanoparticle formulations (Figure 5.5). The native GC-SPIO
nanoparticle was found to have a near-neutral zeta potential (+0.3 mV) at physiologic pH
= 7.4. It is important for tumor delivery that the native GC-SPIO have little or no positive
surface charge at normal blood pH, since cationic materials are rapidly cleared from
circulation, due to local electrostatic interactions, before they could reach a tumor.29
Next, as the pH was lowered, the zeta potential continually increased and reached a value
of +4.1 mV at pH = 6.65 and +8.2 mV at pH = 6.15. Therefore, it was confirmed that the
native GC-SPIO nanoparticles had a surface coat capable of meaningfully sensing a pH
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drop of 1.0 unit or less. Since a wide variety of cationic materials have been found to
electrostatically associate with cells25-28, it was expected that the surface properties of the
native GC-SPIO nanoparticles would allow them to adhere to cells or negatively charged
cellular matrix components in a pH-dependent manner that is favorable for detection of
acidic environments.

Figure 5.5. Zeta potential (surface charge) titration of native GC-SPIO, glycidol GC-SPIO and dextran
SPIO nanoparticles at 100 µg/mL nanoparticle concentration in 10 mM HEPES buffer at various pH.

The pH-dependence of the surface charge was similarly investigated for the
glycidol GC-SPIO and dextran SPIO nanoparticles (Figure 5.5). At physiologic pH = 7.4,
the zeta potentials were -2.9 mV and -20.4 mV for the glycidol GC-SPIO and dextran
SPIO, respectively. Upon lowering of the pH to 6.15, the zeta potentials changed to -1.0
mV and -20.7 mV. These results indicate that the surface charge of the control
nanoparticles does not have significant pH dependence; under conditions that lead to an
increase in the zeta potential of the native GC-SPIO by 7.9 mV, the glycidol GC-SPIO
increased only 1.9 mV, and the dextran SPIO zeta potential dropped by 0.3 mV (a
difference within the standard deviation of a given measurement). It should be noted that
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the zeta potential of both control nanoparticles remains below 0 mV under every pH
condition, such that not even an extremely acidic tumor environment would be able to
induce electrostatic adherence of these nanoparticles.
It should be noted that the two GC-based nanoparticle formulations have similar
(close to neutral) surface charge at physiologic pH = 7.4. In fact, their surface charges
proved similar enough to give them overlapping blood circulation profiles (see below).
The glycidol GC-SPIO control formulation, therefore, specifically isolates the EPR
component of tumor delivery from the native GC-SPIO formulation, so that pH-mediated
improvement can be assessed. The -20 mV dextran nanoparticles, along with dextran
formulations investigated at other charges,24 have zeta potentials encompassing the
charge of native GC-SPIO at physiologic pH. Variations in surface charge can lead to
differences in blood circulation times, and therefore, tumor delivery by EPR. Therefore,
the dextran formulations make it possible to see if the delivery of native GC-SPIO
compares favorably to the delivery obtainable by EPR alone, at any surface charge.

Table 5.1 Summary of the physicochemical properties of native GC-SPIO, glycidol GC-SPIO, and
dextran SPIO nanoparticles.
Particle
Surface

Tracer
Lanthanide

Mean
Hydrodynamic
Diameter (nm)
33.6

Mean
Core Size
(nm)*
19.8 ± 3.6

Zeta (mV)
at pH =
7.4
+0.3

Zeta (mV)
at pH =
6.15
+8.2

R2
(mM-1s-1)

R1
(mM-1s-1)

Native
Gd
146.5
7.5
GC
Glycidol
Gd
36.1
19.8 ± 3.6
-2.9
-1.0
152.3
7.9
GC
Dextran
Sm
29.8
19.4 ± 3.9
-20.4
-20.7
150.4
10.0
*Since the glycidol GC-SPIO was generated by direct surface modification of native GC-SPIO, core sizes
for these formulations are identical.
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In Vitro pH Dependent Association of Native GC-SPIO
Following the successful synthesis of the native GC-SPIO, possessing a favorably
pH-dependent surface charge, as well as size and relaxivity matched pH-independent
control nanoparticles, the ability of each formulation to label tumor cells in vitro and
generate in vitro MR contrast was investigated under various pH conditions. Specifically,
each nanoparticle formulation was incubated in triplicate with T6-17 tumor cells in
culture medium at a concentration of 25 µg Fe/mL at pH values ranging from 5.9 to 7.65,
in 0.25 unit increments. Following triplicate washing to remove unassociated
nanoparticles, the T2 relaxation times of the cell suspensions were measured to access the
extent of cell association (Figure 5.6).

Figure 5.6 In-vitro association of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO nanoparticles
with T6-17 cells. Nanoparticles were incubated in triplicate at 25 µg Fe/mL with 4 x 106 T6-17 cells in
culture medium buffered by 25 mM HEPES. After removal of unassociated nanoparticles, T2 relaxation
times were collected for each cellular suspension.
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Interestingly, it was found that cells incubated with native GC-SPIO nanoparticles
exhibited a pronounced pH-dependence to their T2 relaxation times. At physiologic pH =
7.4, the native GC-SPIO cells had an average T2 relaxation time of 917 ms that was not
statistically different from the T2 relaxation times of cells incubated with either control
nanoparticle or blank cells incubated without nanoparticles. However, when the pH was
dropped only one quarter of a pH unit to 7.15, the average T2 relaxation time of native
GC-SPIO incubated cells dropped to 728 ms. Although not a particularly robust T2 value,
728 ms was statistically different from the values of 950 ms and 927 ms observed for
cells incubated without nanoparticles or glycidol GC-SPIO control nanoparticles,
respectively. These results suggest that, under ideal conditions, the pH-titratable native
GC-SPIO nanoparticles can differentially label cells in microenvironments only 0.25 pH
units below physiologic value. After another 0.25 unit drop in pH to 6.90, the native GCSPIO nanoparticle incubated cells obtained an average T2 value of 553 ms, which was
statistically different from blank cells and cells incubated with both control nanoparticle
formulations. With further reductions in the incubation pH, the average T2 value for cells
incubated with native GC-SPIO continued to decrease, ultimately reaching values of 147
ms at pH 6.15 and 96 ms at pH 5.90.
Appropriately, neither the glycidol GC nor dextran SPIO control nanoparticles
exhibited any meaningful pH-dependence in their cellular association. Although the
glycidol GC-SPIO cells incubated at very low pH values (5.90 and 6.15) yielded T2
relaxation times that were statistically different from the value at physiologic pH = 7.4,
the T2 values at low pH were still greater than 700 ms, indicating a weak signal. Recall
that native GC-SPIO incubated cells had already reached this relaxation level at pH 7.15.
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The statistically detectable difference in relaxation for the glycidol GC-SPIO incubated
cells at the two extremes of pH is likely due to a small population of titratable amino
groups remaining despite chemical blockade. For the dextran SPIO, there was no
statistically detectable difference in cell association between the two ends of the pH
spectrum.
It is also noteworthy that native GC-SPIO nanoparticles are able to produce T2
relaxation times under 200 ms in these cell pellet studies at concentrations of only 25 µg
Fe/mL. For comparison, actively targeted SPIO nanoparticles relying on receptor – ligand
interactions have been tested under similar conditions and yielded similar T2 relaxation
times when incubated at concentrations of 150 µg Fe/mL.32 Although such a comparison
is not exact, these results indicate native GC-SPIO nanoparticles may be able to generate
contrast of a magnitude similar to receptor targeted SPIO nanoparticles.
Following measurement of their T2 relaxation times, the cell pellets were
transferred to a well plate and a T2* weighted MR image was acquired (Figure 4B). For
the cells incubated with native GC-SPIO, signal loss can already be discerned at a pH of
7.15, only 0.25 units below physiologic pH. The signal loss becomes more pronounced as
the incubation pH drops to 6.65 and at pH 6.15 and below the signal is lost entirely under
these imaging parameters. Importantly, the cells incubated with glycidol GC and dextran
SPIO control nanoparticles do not exhibit any marked pH-dependence in their MR signal
intensity.
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Figure 5.7 Triplicate samples at each pH were combined into a single well of a 384-well plate and a T2*
weighted MR image was obtained. Pellets with low T2 relaxation times, resulting from the presence of
nanoparticles, appear with reduced signal intensity in the image.

In Vivo MR Contrast Enhancement of Native GC-SPIO
The ability of native GC-SPIO to generate MR contrast significantly greater than
the background EPR effect was confirmed with an in vivo murine tumor model.
Specifically, T6-17 flank tumors were grown in nude mice to a diameter of
approximately 8 mm and then either native GC-SPIO or control nanoparticles at a dose of
10 mg Fe/kg body weight (approximately 0.2 mg of iron per animal) was administered
intravenously. T2* weighted MR images were acquired immediately prior to injection of
nanoparticles and 24 hours after injection (Figure 5.8). The post contrast images of the
native GC-SPIO nanoparticle demonstrated striking relative signal loss in the tumor. In
the pre-contrast image shown, the tumor is located between iso-intense paraspinal and
thigh muscles and is not clearly delineated. In the post-contrast image, however, the
tumor is revealed as a hypo-intense heterogeneous region, with well-defined margins,
exerting a mass effect against the adjacent paraspinal muscle. The heterogeneity of
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intensity in the tumor is likely caused by impaired SPIO diffusion and penetration once
they encounter a micro-region of sufficient acidity, either at the negatively charged
vascular endothelium or within the tumor interstitium. Alternatively, the heterogeneity
may reflect variations in extracellular pH within the tumor.33 Neither the glycidol GC nor
dextran SPIO control nanoparticles yielded significantly visible contrast enhancement
between pre- and post-contrast images.

Figure 5.8 In vivo pre- and post-contrast MR images of nu/nu nude mice with T6-17 flank tumors.
Representative T2* weighted MR images in the axial plane prior to injection (pre-contrast) and 24 hours
after injection (post-contrast) of native GC-SPIO (n=4), glycidol GC-SPIO (n=4) and dextran SPIO (n=3)
nanoparticles. Tumor location is indicated by white arrows.

The MR signal in the tumor regions of interest (ROIs) were also analyzed
quantitatively (Figure 5B). For each animal, three matching axial slices were examined
pre- and post-contrast. Variations in absolute signal from slice to slice, due to mouse or
RF coil positioning, were accounted for by normalizing the tumor signal to that of
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adjacent paraspinal muscle on a slice by slice basis. The native GC-SPIO nanoparticles
yielded a contrast enhancement (relative signal intensity ratio) of 0.50. In this scale,
lower values indicate greater contrast, with 1.0 corresponding to no contrast and 0
indicating perfect contrast. Importantly, the contrast enhancement observed for native
GC-SPIO nanoparticles was statistically different from that of glycidol GC and dextran
SPIO, which had RSI ratios of 0.86 and 0.84, respectively.

Figure 5.9 Quantitative analysis of MR images of native GC-SPIO (n=4), glycidol GC-SPIO (n=4) and
dextran SPIO (n=3). Signal intensity of each tumor was normalized to adjacent paraspinal muscle. For
contrast measurement, the relative signal intensity, RSI, was calculated as the quotient of the post-contrast
to pre-contrast normalized tumor intensity. For t-test statistical analysis of the groups, statistically
significant values of p<0.05 are indicated with single asterisk and p<0.005 with double asterisk.

Interestingly, the RSI ratio obtained for these native GC-SPIO nanoparticles was
comparable to that obtained in a study of actively targeted SPIO nanoparticles injected at
the same concentration and directed against the same tumor cell line.32 While many
variables influence the contrast enhancement observed in vivo, it is encouraging to see
that the pH-titratable native GC-SPIO nanoparticles can deliver contrast enhancement on
the same order as actively targeted agents.
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Tumor Delivery and Blood Circulation
To specifically examine the amount of nanoparticle delivery to the tumor, as well
as investigate blood circulation profiles, the nanoparticle formulations were designed
with unique lanthanide metal tracers that can be detected by ICP-MS. Immediately after
the post-contrast images were acquired, each animal was sacrificed and the flank tumors
removed. By comparing the amount of lanthanide tracer present in the excised tumors to
the amount of lanthanide present in the original intravenous injection, the amount of
nanoparticle delivery can be quantified as a percent of injected dose per gram of tumor
tissue (Figure 5.10). Also, these data can be converted into absolute iron concentrations
since the amount of injected material is known. The nanoparticle iron concentrations in
the tumor were thus calculated as 2.5, 4.2, and 6.7 µg/mL for dextran, glycidol, and
native GC-SPIO, respectively.

Figure 5.10 Quantitative tumor delivery of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO.
Percent injected dose per gram of tumor tissue was calculated by measuring the concentration of lanthanide
tracer in excised tumors using ICP-MS. For the native GC-SPIO, this converts to approximately 6.7 µg Fe /
mL. For t-test statistical analysis of the groups, statistically significant values of p<0.05 are indicated with
single asterisk and p<0.005 with double asterisk.
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Interestingly, even though MR imaging yielded similar contrast enhancement for
the glycidol GC-SPIO and dextran SPIO, there was significantly more nanoparticle
delivery for the glycidol GC-SPIO. The contrast enhancement observed in MR images
reflects the combination of many variables, including, but not limited to: concentration of
agent in the tumor, MR pulse sequence parameters (e.g. TE), and nanoparticle relaxation
characteristics (e.g. R2). Specifically, the nanoparticles have a dynamic concentration
range in which they linearly decrease the tissue’s relaxation time. For the SPIO used in
this study the dynamic range, determined during in vitro relaxation measurements, was 1
– 50 µg/mL (Figure 5.11). Little contrast may be observed with nanoparticle
concentrations at the low end of this range, significant improvements in contrast occur
near the middle of the range, and saturation occurs at the top. It is likely that the
nanoparticle concentrations achieved by dextran and glycidol GC-SPIO are very near the
bottom of the dynamic range, still not high enough to generate significant contrast with
the pulse sequence parameters used.

Figure 5.11 MR signal response profile for native GC-SPIO. At T2 values lower than 5 ms, the signal
becomes saturated and a T2 values greater than 900 ms, the signal is not discernibly different from baseline
medium (A). The linear dynamic range of the native GC-SPIO, therefore, falls roughly between 1 – 50 µg
Fe / mL (B).
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The animals injected with native GC-SPIO nanoparticles showed a further
significant increase in tumor delivery from the glycidol GC-SPIO. Importantly, this pHmediated increase in nanoparticle delivery was sufficient to reach a concentration
providing much more MR contrast. This demonstrates the importance of optimizing and
maximizing nanoparticle delivery, since the incremental improvement in delivery (i.e.
from glycidol GC-SPIO to native GC-SPIO) has the possibility to yield significant
contrast improvement. It is envisioned that while a completely passive agent might not
reach a concentration detectable on an MR image, the additional improvement in delivery
obtained by a pH-sensitive agent could result in detectable MR contrast.
It has been well established that entirely passive tumor delivery of nanoparticles
via EPR is a function of the pharmacodynamics of their blood circulation20-23. The two
GC based formulations are of similar size, have a similar (although not exactly identical)
zeta potential at the physiologic pH = 7.4, and have a surface coat constructed from the
same polymer. These two formulations, therefore, were expected to have very similar
blood circulation profiles. This important hypothesis was validated by using ICP-MS to
measure the blood concentration for each nanoparticle as a function of time (Figure 5.12).
As anticipated, the native GC-SPIO and glycidol GC-SPIO were found to have very well
overlapped blood circulation profiles. Importantly, the small difference between the
native GC-SPIO and glycidol GC-SPIO surface charge at physiologic pH did not alter
their blood clearance. Therefore, it can be concluded that the incremental improvement in
delivery that native GC-SPIO exhibits over glycidol GC-SPIO represents pH-mediated
delivery, not attributable to EPR.
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Figure 5.12 Blood clearance of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO (-20 mV) as
measured by concentration of lanthanide tracer in the blood.

In order to see how the pH-enhanced tumor delivery of native GC-SPIO compares
to the EPR that could be obtained with surface charges (other than neutral), it is helpful to
examine the tumor delivery of the dextran SPIO nanoparticles at -20 mV and other zeta
potentials. This can also rule out the possibility native GC-SPIO is simply adopting some
positive charge, within its titration range, that would have produced high delivery even if
the nanoparticle were fixed at that particular charge. Dextran SPIO with pH-independent
zeta potentials of approximately -12 mV, -5 mV, +4 mV, +10 mV and +14 mV were
intravenously administered to animals bearing T6-17 flank tumors Chapter 4.24 Like the 20 mV dextran SPIO nanoparticles in this study, none of the pH-insensitive dextran SPIO
nanoparticles accumulated as well as native-GC SPIO (i.e. statistically significant inferior
delivery for every dextran SPIO nanoparticle, Figure 5.13). The lower delivery observed
for the -20 mV and other charge dextran formulations correlated with their shorter blood
residence times (Figure 5.12), characteristic of delivery by EPR. Importantly, the dextran
SPIO with strongly positive surface charge accumulated especially poorly at the tumor
site. It is, therefore, important for the mechanism of native GC-SPIO delivery that the
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nanoparticles not constitutively display a large positive surface charge – rather only after
entering the tumor microenvironment.

Figure 5.13 Tumor delivery of native GC-SPIO compared to glycidol blocked GC-SPIO and dextran
SPIO formulations with a wide range of pH-insensitive zeta potentials.

Finally, in addition to the pathological environment of a tumor, other groups
investigating pH-responsive agents have demonstrated that there are physiologically
normal sites of pH < 7.4, such as the renal tubular system.34-36 Therefore, the delivery of
native GC and control SPIO nanoparticles to the kidneys was examined. At 24 hours
post-injection, the average renal concentrations, expressed as percent of injected dose per
gram of kidney tissue, were found to be 4.49, 2.40, and 1.02 for native GC-SPIO,
glycidol GC-SPIO and dextran SPIO (-20 mV), respectively (Figure 5.14). Given the
longer blood residence times for the two GC based formulations, it is not surprising to
observe a greater renal concentration at 24 hours for those formulations compared to the
dextran SPIO. Interestingly, though, the renal concentration of the native GC-SPIO was a
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statistically significant 87% higher than that of the glycidol GC-SPIO, despite very
similar blood circulation profiles and identical blood concentrations at the 24 hour time
point. Furthermore, the native GC-SPIO nanoparticles are not simply being deposited to a
higher extent in all organs, since the concentrations of all three nanoparticles in the liver
at 24 hours were not statistically distinct from one another. Despite the lack of statistical
significance, the native-GC SPIO nanoparticles had a trend towards less accumulation in
the liver (33.3 versus 44.9 and 37.9 for the glycidol GC and dextran SPIO, respectively,
Figure 5.14).

Figure 5.14 Kidney and liver concentrations of native GC-SPIO, glycidol GC-SPIO, and dextran SPIO
(-20 mV), 24 hours post-injection. Asterisk indicates statistical significance (p<0.05) between native GCSPIO kidney uptake and either control nanoparticle.
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5.5 Conclusion
The biocompatible and biodegradable polymer glycol chitosan can be used to impart pHresponsiveness to superparamagnetic iron oxide nanoparticles. The resulting material
demonstrates a pH-dependent surface charge, allowing it achieve long blood circulation
at physiologic pH = 7.4 and then transition to a cationic and adhesive form upon entering
an acidic microenvironment pH < 7.0. These native GC-SPIO nanoparticles exhibited
significantly improved accumulation in a murine tumor model, compared to nanoparticles
with similar physical properties, but lacking pH-responsiveness. Higher levels of SPIO
accumulation in the tumor also resulted in a clear and quantifiable improvement in
magnetic resonance contrast, as shown on T2*-weighted images. Generally, it is believed
glycol chitosan could be used to exploit the metabolic profile of a wide range of
malignancies and improve the tumor delivery of imaging or therapeutic agents, provided
that synthesis of such agents preserves the pH-responsive amino group.
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Chapter 6: Summary Discussion, Future Directions and
Concluding Remarks
6.1 Summary Discussion
6.1.1 ICP-MS Multiplexing Analysis Applied in vivo
Since it was first used to analyze amino acids in 1958,1 mass spectrometry (MS)
has become an extremely powerful tool in the investigation of biological samples. For
example, mass spectrometry, combined with powerful computational methods, plays a
critical role in the field of proteomics and metabolomics.2 MS can facilitate the
identification of protein bands on gels using peptide mass fingerprinting3 and can be used
for de novo peptide sequencing.4 When MS is coupled to a very high temperature plasma
source (ICP-MS) elemental analysis of complex biological samples becomes possible.
Recently, it was recognized that unique elemental isotopes (e.g. of lanthanides) could be
used to “tag” biomolecules for identification and quantitation by ICP-MS.5 Given the
very large window of atomic masses not normally observed in biological samples, very
high order multiplex analysis becomes possible. This remarkable capability was very
recently (May 2011) combined with flow cytometry to yield a technique dubbed “mass
cytometry”.6 Specifically, conjugated metal isotopes were used to simultaneously
measure the binding of 31 antibodies to single cells. This detailed level of analysis (3 – 4
times more powerful than state of the art multi-color flow cytometry) revealed previously
unappreciated cell signaling and phosphorylation responses in human hematopoietic
cells. The objective of this thesis was to demonstrate the applicability of ICP-MS
multiplex analysis to supra-molecular assemblies (i.e. nanoparticles), and more
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importantly, pave the way for high-order multiplexing of in vivo data such as
pharmacokinetics and biodistribution.
Firstly, lanthanide metals were used to tag superparamagnetic iron oxide (SPIO),
a promising and widely-researched T2-weighted magnetic resonance contrast agent. A
synthetic protocol to stably incorporate the lanthanide metals into the core of SPIO
nanoparticles, without abolishing their magnetic properties, was developed. The
lanthanide dopant can be used as a unique tracer atom, allowing the sensitive and
quantitative detection of the entire nanoparticle by ICP-MS, both in vitro and in vivo,
without interference from endogenous signals. When distinct lanthanide metals are
incorporated into nanoparticles with distinct physicochemical properties, ICP-MS allows
for the concentration of each nanoparticle formulation to be measured independently of
other formulations that may be present in the solution or tissue of interest. As a proof of
principle, this ICP-MS multiplex approach was used to evaluate the effect of nanoparticle
size and surface charge on tumor delivery, biodistribution, and blood clearance in vivo.
The results obtained were consistent with the general literature consensus about these
properties and only required a small number of experimental animals, due to the inherent
and robust statistical power of a multiplex (ratiometric) approach. Furthermore, it is
envisioned that the ICP-MS multiplex analysis could prove to be a powerful future
research tool in the investigation of other less well-characterized physicochemical
properties.
Secondly, more generalizable methods of lanthanide incorporation were pursued.
It was found that in addition to precipitating lanthanide metals into the core of SPIO
nanoparticles, it is also possible to incorporate lanthanides into liposomes,
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polymersomes, and dendrimeric formulations using either encapsulation or chelation.
Therefore, it is envisioned that any nanoparticle formulation amenable to labeling with a
metal radionuclide would also be suitable for labeling with an ICP-MS metal tracer.
Some other types of nanoparticles (e.g. gold and silver nanoparticles) inherently contain
an ICP-MS metal tracer, without any further need for labeling. In addition to providing a
quantitative method of detection with high sensitivity, ICP-MS tracers provide two
potential benefits over conventional radiolabeling. Namely, they have the ability to easily
multiplex a large number of signals in a single fluid or tissue sample while avoiding the
hazards of handling radioactivity. Consequently, ICP-MS based multiplex analysis can be
applied to a very wide variety of nanoparticle and macropharmaceutical formulations and
allows for “higher throughput” evaluation of the pharmacokinetics and biodistribution of
such agents in animals models.
Since active targeting of pathologies in vivo at the molecular level is an extremely
promising and actively pursued strategy in nanotechnology, we sought to demonstrate
how ICP-MS multiplexing could be exploited to streamline the evaluation of actively
targeted nanoparticles in vivo. Specifically, SPIO nanoparticles were synthesized with a
variety of lanthanide tracer metals and all had overlapping size distributions, so that they
exhibit equal levels of passive tumor accumulation. These Ln-SPIO formulations were
then be subsequently functionalized with active targeting ligands, such that each targeting
ligand is associated with a specific lanthanide tracer. The binding of these nanoparticles
to two tumor cell lines, with varying expression levels of three specific receptors, was
examined in vitro with conventional methods such as flow cytometry. Then ICP-MS
analysis was used to independently quantify the cell labeling of each nanoparticle,
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compared to a non-targeted formulation, in a single sample. Therefore, it should become
feasible in a single study to investigate in vivo many nanoparticle active targeting and
negative control formulations, collecting data such as nanoparticle blood residence time,
tumor delivery, and biodistribution. This represents a powerful tool for nanotechnology
investigators to more thoroughly evaluate a greater number of nanoparticle formulations
in vivo, while reducing experiment time, cost, and number of animals.

6.1.2 Development of pH-Responsive SPIO
Another major avenue of investigation in this thesis was the design of a novel
pH-sensitive SPIO nanoparticle for relative pH imaging of acidic tumor
microenvironments. Such an approach provides a complimentary approach to
absolute pH imaging by MRS (where the pH is determined by the chemical shift of
the probe) or CEST (where changes in pH influence the chemical exchange kinetics).
With a relative pH probe, the goal is to detect regions of relatively abnormal pH by
designing agents that preferentially accumulate in these regions. That is, the identity
of the signal is not influenced by pH, but the biodistribution of the agent is influenced
by pH. In this respect, such an agent has much in common with a classic
receptor/ligand actively targeted molecule; the agent washes into the tumor through
the enhanced permeability of the tumor vasculature and then is preferentially retained
at the tumor site through pH mediated alterations in the nanoparticle’s
physicochemical properties.
It was found that the biocompatible and biodegradable polymer glycol chitosan
can be used to impart pH-responsiveness to superparamagnetic iron oxide nanoparticles.
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The resulting material demonstrates a pH-dependent surface charge, allowing it achieve
long blood circulation at physiologic pH = 7.4 and then transition to a cationic and
adhesive form upon entering an acidic microenvironment pH < 7.0. These native GCSPIO nanoparticles exhibited significantly improved accumulation in a murine tumor
model, compared to nanoparticles with similar physical properties, but lacking pHresponsiveness. Higher levels of SPIO accumulation in the tumor also resulted in a clear
and quantifiable improvement in magnetic resonance contrast, as shown on T2*-weighted
images. Generally, it is believed glycol chitosan could be used to exploit the metabolic
profile of a wide range of malignancies and improve the tumor delivery of imaging or
therapeutic agents, provided that synthesis of such agents preserves the pH-responsive
amino group.

6.2 Future Directions
6.2.1 Completion of Active Targeting Comparison in vivo
In chapter 4, we used ICP-MS multiplex analysis to evaluate cell labeling of
multiple actively targeted SPIO nanoparticles, compared to a non-targeted formulation,
all in a single in vitro measurement. The final logical experiment, clearly, is to complete
the in vivo characterization of these nanoparticles. Specifically, the HER2-SPIO, RGDSPIO, LDS-SPIO, and Blank-SPIO will be pooled into a single sample and administered
intravenously to tumor bearing mice. Optimally, the animal subjects will bear both the
“receptor-high” T6-17 tumors and “receptor low” HeLa tumors on opposite flanks. This
will allow blood clearance of the four Ln-SPIO formulations, as well as tumor delivery to
both cell lines, to be evaluated in a single animal.
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6.2.2 Future Applications of in vivo ICP-MS Multiplex Analysis
This thesis only begins to explore the possibilities of what information can be
obtained from in vivo use of ICP-MS multiplex analysis. For example, the effect of SPIO
nanoparticle size and charge on passive tumor delivery and biodistribution were assessed,
so that the results obtained could be compared to the general literature consensus of these
effects.7-10 However, there are many other physicochemical properties (e.g. shape, surface
chemistry, elasticity, and other mechanical properties) that can affect nanoparticle tumor
delivery and biodistribution, all of which are less fully understood and could be
investigated using this method.
Additionally, the ICP-MS multiplex method could aid in the evaluation of more
nuanced questions in the field of nanoparticle active targeting. Specifically, the ICP-MS
multiplex approach could be used to compare variations of a given actively targeted
nanoparticle. For example, different ligand types, such as an antibody, single chain
antibody fragment (scFv), or small affinity peptide could be quantitatively compared. Or,
within a given class of ligand, different specific sequences could be compared (i.e.
several affinity peptide sequences obtained from phage display). Furthermore, it is being
appreciated that optimal cell binding and in vivo delivery is not necessarily achieved by
coating a nanoparticle with the maximum possible ligand density. Thus, ICP-MS
multiplex analysis presents a powerful tool to evaluate the effect of ligand density. Also,
active targeting of nanoparticles displaying ligands for two or more targets could be
compared against more conventional single ligand formulations.
The ICP-MS multiplex approach could also be adapted to more specialized
research questions. For example, nanoparticle trafficking and metabolism could be
probed by labeling different components of the nanoparticle with different lanthanides
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(e.g. encapsulating one metal within a liposome core and chelating another metal to the
lipid membrane component). Or chelation stability could be evaluated in vivo by
constructing a given nanoparticle formulation but using different chelators to incorporate
the metal. In general, it is envisioned the ICP-MS multiplex method could be exploited to
answer any research question involving the in vivo comparison of two or more agents that
are amenable to lanthanide labeling.
Furthermore, it is envisioned that the spatial distribution of each nanoparticle
within an organ or other tissue sample could also be obtained with the use of laser
ablation ICP-MS.11 With LA-ICP-MS, the tissue sample is directly vaporized, layer-bylayer, with a pulsed laser and transported into the mass analyzer.12 Another potential
advantage of LA-ICPS-MS is the ability to process microgram samples sizes, which
could be required for the analysis of smaller organs or specialized tissue (e.g. lymph
nodes, adrenal glands).

6.2.3 Use of ICP-MS Multiplex Analysis to Generate Standardized
Data
Another promising application of this multiplex ICP-MS method is the potential
to generate standardized data that can be compared between studies and between
laboratories. With so many research groups engaged in the development of nanoparticles,
a myriad of different formulations have been synthesized for both imaging and
therapeutic applications.13 Even when nanoparticle (payload) delivery is quantitatively
reported, it is difficult for one group to ascertain whether their formulation resulted in
better delivery than another’s, given the numerous variables, known and unknown,
involved in an in vivo study. This is a particularly significant problem in the nanoparticle
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field, and one that hinders the progress of nanoparticles into clinical evaluation.14
However, if a rigorously standardized and highly reproducible lanthanide-doped
nanoparticle (such as a G5 dendrimer with tightly chelated lanthanide) were available,
each group could co-inject the standardized nanoparticle along with their investigational
one. The delivery of the investigational agent could, therefore, be reported not only in
absolute terms, but also as a ratio to the standardized particle. Such a ratiometric
approach could facilitate accurate comparisons between various investigational agents.

6.2.4 Future Applications of pH-Responsive Glycol Chitosan and
SPIO
Chapter four of this thesis demonstrated the success of using a glycol chitosan
(GC) coating to increase the tumor delivery of SPIO nanoparticles based on tumor
acidity. There are a number of possible ways to improve and adapt this approach for
future investigational agents. For example, glycol chitosan is only one of a number of
pH-responsive polymers or peptides that could be used to sense relative changes in pH.
Future work could focus on using GC or another polymer to optimize the nanoparticle’s
titration curve, with respect to starting zeta potential at physiologic pH, the pH at which
charge transition begins to occur, and the steepness of the charge switch. Such studies
could lead to an agent capable of sensing smaller deviations in pH while further reducing
background accumulation at physiologic pH values.
Secondly, GC itself could be investigated as a pH sensor for imaging and
therapeutic platforms in addition to SPIO. For example, a T1-weighted MR contrast agent
could be developed by decorating a fraction of GC’s functional amino groups with small
generation dendrimers, each carrying many gadolinium chelates. Similarly, incorporation
185

of

64

Cu chelates could produce a novel pH-sensitive PET probe. Beyond imaging

applications, GC could be incorporated into the design of drug-carrying nanoparticle
formulations (e.g. polymeric micelles or nanovesicles) in order to facilitate
chemotherapeutic delivery to tumors.
Finally, it may be possible to use the pH-dependent titration of GC to make
measurements of absolute pH using chemical exchange saturation transfer (CEST). That
is, the amine protons of the glycol chitosan should exhibit variable chemical exchange
kinetics depending on the pH of their local environment. If a lower molecular weight
form of GC were administered with large enough concentration, a saturation pulse could
be applied on its N-H resonance, and the rate of saturation transfer to bulk water could be
used as a pH meter in vivo.

6.3 Concluding Remarks
Over the last two decades, the development of quantitative high-throughput
analytical methods has revolutionized the process of molecular discovery and
characterization in vitro. ICP-MS is increasing being used in these kinds of parallel
processing of biological samples in vitro, as evidenced by the recent development of
mass cytometry. In the future, we envision that “higher-throughput” evaluation of agents
at the in vivo level using ICP-MS multiplex analysis may constitute a powerful tool to
accelerate their pre-clinical evaluation in animal models. Further improvements to
modularity and automation of lanthanide labeling (i.e. massively parallel conjugation of
preformed metal-chelate complexes to macropharmaceuticals in robotically controlled
reactions) would facilitate the use of in vivo ICP-MS multiplex analysis on a wider scale.
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